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„Wir streben mehr danach, Schmerz zu vermeiden als Freude 
zu gewinnen.“ 
 
 
(We will do more to avoid pain 
than to gain pleasure) 
 
Sigmund Freud (1856-1939) 
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I. Summary   
 
The biological importance of the nociception and pain is to alert us of potentially tissue-
damaging or noxious events and protect us from damage. However, as a result of injury 
nerve damage or inflammation, pain can become chronic. It, then, no longer serves a 
physiological function, but can severly interfere with our well-being. Such chronic pain 
syndromes are often unresponsive to conventional analgesic treatment and hence constitute 
a major medical and socio-economical problem worldwide. In the last decade, it has become 
increasingly clear that a loss of spinal inhibition, normally provided by γ-aminobutyric acid 
(GABA)ergic and glycinergic interneurons, plays a role in the generation and maintenance of 
chronic pain. Pharmacological facilitation of GABAergic inhibition could thus be a rational 
approach to the treatment of chronic pain, but wide-spread sedative action and other 
undesired actions prevent their use in chronic pain patients. 
In the first project of this thesis, GABAA receptor point-mutated (knock-in) mice have been 
used, in which specific GABAA receptor subtypes have been rendered insensitive to 
diazepam (a classical benzodiazepine). Experiments with these mice demonstrate that 
pronounced analgesia can be achieved by specifically targeting spinal GABAA receptors 
containing the α2 and/or α3 subunits. In line with these findings from genetically modified 
mice, pharmacological experiments demonstrate that the selective targeting of α2 and/or α3 
GABAA receptors by the non-sedative (‘α1-sparing’) benzodiazepine-site ligand L-838,417 is 
highly effective against inflammatory and neuropathic pain, yet devoid of unwanted sedation, 
motor impairment and tolerance development.  
The second project adresses the mechanisms of this analgesia. At the level of the spinal 
cord, GABAA receptors are expressed not only postsynaptically on dorsal horn neurons, but 
are also found at the spinal terminals of primary afferent nociceptors where they contribute to 
presynaptic inhibition through primary afferent depolarization (PAD). Many of these 
presynaptic GABAA receptors belong to the α2 subunit containing type (α2-GABAA 
receptors), which mediates most of the analgesic action of spinal diazepam. Experiments 
with conditional, nociceptor-specific α2-GABAA receptor deficient (sns-α2-/-) mice, and 
conditional (sns-α2R/-), point-mutated mice, whose primary nociceptor α2-GABAA receptor 
subunits have been rendered diazepam-insensitive, revealed unchanged nociceptive 
baseline thresholds and unchanged inflammatory and neuropathic hyperalgesia, but 
decreased diazepam-induced analgesia against inflammatory pain.  
In the last project, the generation of a novel Homeobox-8-cre (Hoxb8-cre) transgenic mouse 
line is reported, which expresses the cre recombinase under the transcriptional control of the 
Hoxb8 gene. This mouse line shows a cre expression pattern monitored by reporter gene 
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mouse lines (e.g. Rosa26lacZ) suitable for brain-sparing gene deletion experiments In the 
context of GABAergic analgesia, it will help defining the contritution of spinal versus 
supraspinal sites to GABAA receptor-mediated analgesia.  
The results from this dissertation contribute to the development of a rational basis for the 
development of subtype-selective GABAA receptor ligands for the treatment of chronic pain, 
which is often refractory to classical analgesics.  
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II. Zusammenfassung (German Summary) 
 
Schmerz ist eine komplexe Sinneswahrnehmung, die als akutes Geschehen den Charakter 
eines Warnsignals aufweist. Infolge von Nervenschädigungen oder Entzündungen kann 
Schmerz jedoch chronisch werden und die ursprüngliche physiologische Funktion verlieren. 
Chronische Schmerzen führen zu teilweise erheblichen Behinderungen, die nicht nur 
individuelles Leiden auslösen und die Lebensqualität einschränken, sondern einen Einfluss 
auf viele Bereiche des Lebens haben. Chronische Schmerzen können nur selten adäquat mit 
den herkömmlichen Schmerzmitteln (Analgetika) behandelt werden.  
In den letzten zehn Jahren wurde dank medizinischer Grundlagenforschung klar, dass ein 
Verlust an spinaler Hemmung, normalerweise durch GABAerge und glycinerge 
Interneuronen vermittelt, eine wesentliche Rolle in der Entstehung und Verlauf des 
chronischen Schmerzes spielt. Eine pharmakologische Verstärkung der GABAergen 
Hemmung sollte daher einen rationalen Ansatz zur Behandlung von chronischen Schmerzen 
bieten. Eine generelle Verstärkung der GABAergen Hemmung führt jedoch nicht selten auch 
zu unerwünschten Wirkungen (z.B. Sedation), die den Einsatz solcher Medikamente in der 
Klinik stark einschränken. 
Im ersten Projekt dieser Dissertation wurden genetisch manipulierte Mäusen untersucht, die 
Punktmutationen an verschiedenen GABAA Rezeptor Untereinheiten aufweisen, welche zur 
Insensitivität gegenüber klassischen Benzodiazepinen (z.B. Diazepam) führen. Experimente 
mit diesen Mäusen zeigten, dass eine gezielte Aktivierung von spinalen GABAA Rezeptoren, 
die die α2 und/oder α3 Untereinheiten haben, zur Analgesie führen. Diese Ergebnisse 
konnten pharmakologisch untermauert werden, indem ein subtypspezifischer (keine 
pharmakologische α1 Aktivität), nicht-sedativer Ligand (L-838,417) an der Benzodiazepin-
Bindungsstelle, verwendet wurde. Dieser Ligand führte in Entzüngsschmerz- und 
Neuropathiemodellen zur Analgesie ohne Sedation, motorische Störungen oder 
Gewöhnungseffekte aufzuweisen. 
Das zweite Projekt ging dem Mechanismus dieser spinalen Analgesie nach. Auf der Ebene 
des Rückenmarks sind GABAA Rezeptoren nicht nur postsynaptisch auf Neuronen im 
Vorderhorn des Rückenmarks präsent, sondern auch auf den spinalen Endigungen von 
nociceptiven Afferenzen, wo sie zur präsynaptischen Inhibition durch das Phänomen der 
primär afferenten Depolarisattion (PAD) beitragen. Viele dieser präsynaptischen GABAA 
Rezeptoren enthalten die α2 Untereinheit, welche sich im ersten Projekt als wichtigste 
Untereinheit für die spinale analgetische  Diazepam-vermittelte Wirkung erwiesen hatte. 
Experimente mit Mäusen, die eine Nociceptor-spezifische Deletion des GABAA Rezeptor α2 
aufweisen (sns-α2-/- Mäuse), oder eine Diazepam-insensitive α2 Untereinheit exprimieren 
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(sns-α2R/- Mäuse), zeigten, dass sowohl die basale Schmerzschwelle als auch der Verlauf 
der Hyperalgesie in Entzündungs- und Neuropathiemodellen in diesen Mäusen nicht 
vermindert waren. Weitere Experimente konnten jedoch zeigen, dass im Entzündungsmodell 
die Diazepam-induzierte Analgesie deutlich vermindert war. 
Im letzten Projekt ist die Entwicklung eine neuen transgenen Mauslinie (Hoxb8-cre) 
beschrieben, welche die Cre Recombinase unter der transkriptionalen Kontrolle des 
Entwicklungsgens Hob8 exprimiert. Die morphologische Charakterisierung dieser Mauslinie 
mittels Reporter-Mauslinien (z.B. Rosa26lacZ) zeigte, dass diese Mauslinie geeignet ist, um 
Gene im Nervensystem unter Aussparung des Gehirn zu deletieren. Im Kontext der 
GABAergen Analgesie könnte diese Mauslinie daher zur weiteren Klärung der GABAergen 
Analgesie der spinalen versus supraspinaler Ebene dienen. 
Die Ergebnisse dieser Dissertation haben zum Verständnis und zur Grundlage eines 
rationalen Ansatzes für die Entwicklung von Subtyp-spezifischen GABAA Rezeptor Liganden 
beigetragen, welche eventuell zur Behandlung von chronischen Schmerzen eingesetzt 
werden können. 
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Zeilhofer HU, Witschi R, Johansson T: Fast Inhibitory Transmission of Pain in the Spinal 
Cord” in: Malcangio M: Synaptic Plasticity in Pain. Springer, New York, 2009. 
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1. General Introduction 
1.1 Definition and Epidemiology of Pain 
Pain is defined by the International Association for the Study of Pain (IASP) as “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage” (Bonica, 1979). A recent telphone survey in 
Europe found that around 20% of individuals have some form of chronic pain defined in this 
study as pain lasting for at least 6 months (Breivik et al., 2006). Chronic pain hence 
constitutes a major medical and socio-economical problem. According to the American 
Chronic Pain Association (www.theacpa.org), the annual total of both direct and indirect 
costs of chronic pain are estimated to be as high as $294.5 billion per year, with back pain 
alone accounting for more than $100 billion per year. 
Plenty of evidence indicates that chronic pain is not just prolonged acute pain, but results at 
least in parts from plastic changes in the processing of sensory and nociceptive (painful) 
stimuli at all levels of the neuraxis. Much has been learned about molecular and cellular 
processes underlying the transduction and transmission of acute nociceptiove stimuli, but our 
knowledge about the pathology underlying chronic pain is still very limited. A similar situation 
exists in pain treatment. Acute pain can often be controlled effectively with the available 
analgesics, in particular with opioids, such as morphine, and non-steroidal anti-inflammatory 
drugs (NSAIDs), which inhibit the formation of pronociceptive prostaglandins through 
blockade of the cyclooxygenases, COX-1 and COX-2. In chronic pain syndomes, however, 
reduced tolerability and efficacy often limit the therapeutic effects of currently available 
analgesics (Pezet and McMahon, 2006). Chronic use of opioids can lead to physical 
dependence and addiction, while conventional NSAIDs can cause severe gastrointestinal 
side effects and both conventional NSAIDs and COX-2-selective agents increase the risk of 
adverse cardiovascular events. Furthermore, not all pain forms respond well to opioids or 
NSAIDs, and many forms of chronic pain are largely resistant to these analgesics. Because 
of these limitations, many efforts are currently undertaken to better understand the 
neurobiological bases of chronic pain and to foster the development of novel therapeutic 
approaches. 
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1.2 Neurobiology of Pain 
The next chapters shall provide an overview over the neuroanatomical and physiological 
substrates of acute nociception and introduce concepts of spinal mechanisms of peripheral 
and central sensitization. 
1.2.1 Neuroanatomical and Physiological Substrates of Nociception 
All higher organisms process specialized nerve cells, called nociceptors, which consitute a 
class of primary sensory neurons dedicated to the detection of noxious (potentially tissue 
damaging) stimuli. The peripheral axons of these noccieptors innervate the skin, many 
visceral organs, and skeletal and cardiac muscle where they are often found in association 
with blood vessels. The cell bodies of nociceptors innervating the head are located in the 
trigeminal ganglia, while the others are located in the dorsal root ganglia (DRG). The central 
axons of nociceptors terminate in the superficial layers of ipsilateral trigeminal nucleus or in 
spinal dorsal horn, respectively. Most nociceptive nerve fibers are thin slowly conducting 
nerve fibers and belong either to the unmyeliated C fiber or to the thinly myelinated Aδ fiber 
class. However, some nociceptors are also found among the think myelinated Aβ fibers. The 
majority of the touch-sensitive (low-threshold) mechanoreceptors belong to this fiber class. 
They have the fastest conduction velocities of all sensory nerve fibers and before projecting 
to directly to the brainstem they send collaterals to neurons in the deeper laminae of the 
spinal cord dorsal horn. 
Different nociceptor types trigger different pain sensations. Activation of Aδ fibers results in a 
fast sharp and clearly localized pain, while C fiber activation evokes a more prolonged dull 
and burning pain sensation. There is also evidence that different types of nociceptors are 
activated by different stimuli. At least in mice, acute noxious mechanical stimuli are mainly 
detected by Aδ fibers and non-peptidergic (isolectin B4-positive) C fibers, while heat 
responses are triggered by activation of peptidergic C fibers (Basbaum et al., 2009; Seal et 
al., 2009). The latter class of nociceptors contains in addition to the fast excitatory 
neurotransmitter L-glutamate, neuropeptides in particular calcitonin gene-related peptide 
(CGRP), which upon release in the peripheral tissue acts as a vasodilator and mediates the 
so called flare response after C fiber stimulation. Some mechano-insensitive (“silent”) 
nociceptors aquire mechanosensitivity after prolonged stimulation or under inflammatatory 
conditions (Schmidt et al., 2000; Schmidt et al., 2002).  
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Figure 1. Spinal Cord Dorsal Horn.  
 
Nociceptive afferent fibers terminate in the superficial layers of the dorsal horn of the spinal cord. 
Projection neurons in lamina I receive direct input from Aδ and C nociceptors. Lamina V neurons are 
predominantly of the wide dynamic-range type. They receive input from low-threshold large-diameter 
myelinated fibers (Aβ) of mechanoreceptors as well as both direct and indirect input from nociceptive 
afferent fibers (Aδ and C). In this figure the lamina V neuron sends a dendrite up through lamina IV, 
where it is contacted by the terminal of an Aβ primary afferent. A dendrite in lamina III arising from a 
cell in lamina V is contacted by the axon terminal of a lamina II interneuron. Adapted from (Kandel et 
al., 2000). 
 
In the last 15 years, researchers have begun to understand the signal transduction in 
nociceptor terminals on a molecular level. It has been found that transient receptor potential 
(TRP) channels play a crucial role in the transduction of thermal (heat and cold) stimuli. One 
of these TRP channels, the TRPV1 (Davis et al., 2000; Prescott and Julius, 2003; Eckert et 
al., 2006) channel, serves as an integrator of different noxious stimuli including heat (>43°C) 
and tissue acidosis in inflammation and ischemia. This ion channel can be specifically 
activated by capsaicin, the hot tasting ingredient of peppers. TRPA1 is another TRP channel 
expressed by nociceptors, which is activated by a wide variety of chemical stimuli including 
tear gas, mustard oil, and by noxious cold. These TRP channels are non-specific cation 
channels, which upon opening depolarize the nociceptor terminal to levels sufficient to elicit 
action potentials.  
The central axons of Aδ and C nociceptors terminate mainly in the superficial layers (laminae 
I and II, (Rexed, 1952)) of the spinal cord dorsal horn with peptidergic C fibers terminating 
mainly in lamina I and II outer (IIo) and non-peptidergic C fibers terminating mainly in lamina 
II inner (IIi) (Hunt and Mantyh, 2001; Zylka, 2005). Both nociceptor types use L-glutamate as 
their principle fast exciatory neurotransmitter and excite “pain-specific” projection neurons 
located in lamina I through either mono- or polysynaptic connections. L-glutamate acts 
primarily on ionotropic glutamate receptors, of the α-amino-3-hydoxy-5-methyl-4-
isoxazolepropionic acid (AMPA)/kainate type. N-methyl-D-aspartate (NMDA) receptors 
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contribute only little to acute postsynaptic excitation because these receptors are tonically 
blocked by extracellular Mg2+ (Davies and Lodge, 1987; Dingledine et al., 1999) but are 
important for plastic changes in nociceptive processing.  
The axons of projection neurons cross the midline and ascend mainly in the spinoreticular 
and spinothalamic tract to the brainstem and the thalamus. The perception of pain involves 
sensory-discriminative, affective-motivational and cognitive-evaluative dimensions. These 
different aspects of pain are represented in distinct pain pathways and brain regions 
activated during the experience of pain (the so called pain matrix). The ‘‘lateral pain system’’ 
includes the primary (S1) and secondary (S2) somatosensory cortices that receive input from 
the lateral thalamic nuclei and reflects the sensory and discriminative components (location 
and intensity) of pain. Another pathway (‘‘medial pain system“) branches at the level of the 
medulla and ascends via the medial thalamus to hypothalamic nuclei, limbic regions including 
the anterior cingulate cortex (ACC), the insula cortex (IC) and onto prefrontal areas, all of 
which are involved in the control of emotion, arousal and attention. This medial pain pathway 
is therefore proposed to mediate the unpleasant, affective dimensions of pain, and the 
motivation to escape from the noxious event (Treede et al., 1999; Price, 2000; Brooks and 
Tracey, 2005; Bushnell, 2006).  
 
 
Figure 2. Schematic of afferent 
pathways underlying the 
sensation of pain.  
 
Injury activates primary afferent 
nociceptors (PAN), which transmit 
information to the dorsal horn of the 
spinal cord. The terminals of the 
PAN contact neurons in specific 
laminae of the dorsal horn where 
they release glutamate and neuro-
peptides to activate second order 
neurons. The axons of nociceptive 
dorsal horn neurons cross to the 
contralateral anterolateral quadrant 
to form an ascending tract, which 
terminates in the brainstem and 
several distinct areas of the 
thalamus, which contain higher 
order neurons that project to 
various cortical regions that 
mediate different aspects of the 
pain experience. These regions 
include somatosensory, anterior 
cingulate and insular cortices. SMT, 
spinomesencephalic tract; SRT, 
spinoreticular tract. Adapted from 
(Fields, 2004). 
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1.2.2 Peripheral and Spinal Pain Sensitization  
Many chronic pain forms are accompanied by abnormal pain sensitivity, which can be 
classified as hyperalgesia (increased pain to mild noxious stimuli), allodynia (touch-evoked 
pain) or spontaneous pain ocurring in the absence of any sensory stimulation. Hyperalgesia 
occurring at the site of injury is called primary hyperalgesia, while enhanced pain sensitivity 
in uninjured healthy tissue is termed secondary hyperalgesia. Both peripheral and central 
processes can contribute to primary hyperalgesia and probably also to spontaneous pain, 
whereas secondary hyperalgesia and allodynia originate exclusively from central 
sensitization. 
Peripheral hyperalgesia is frequently triggered by pro-inflammatory mediators including 
among others prostaglandins (mainly PGE2 and PGI2), bradykinin, and NGF, which increase 
the excitability of nociceptors. Some of these mediators have been shown to facilitate the 
activation of TRP channels in particular of TRPV1 channels and of voltage-gated sodium 
channels (e.g. NaV1.8) through protein kinase A (PKA) or PKC dependent phosphorylation 
or through changes in the expression of the respective genes (Tate et al., 1998; Michael and 
Priestley, 1999; Bhave et al., 2002; Hudmon et al., 2008). 
Several different concepts exist about the changes in the spinal processing of sensory and 
nociceptive processing that underlie chronic pain syndromes. Intense and prolonged 
nociceptive input to the spinal dorsal horn leads to short-term and long-term increases in 
synaptic excitability of dorsal horn neurons. Repetitive stimulation of C fibers leads to a 
frequency-dependent temporal summation of postsynaptic potentials which results in 
increased excitability of dorsal horn neurons (wind-up; (Herrero et al., 2000)). A wide variety 
of mediators and receptors including glutamate acting on NMDA receptors, substance P on 
NK1 receptors, probably contribute to this form of short-term plasticity. A behavioral correlate 
of wind-up can be observed after repeated heat or noxious mechanical stimulation, where felt 
pain intensities increase with each successive stimulus even though the stimulus intensity 
does not change (Price et al., 1977; Staud et al., 2003). 
Another longer lasting phenomenon of increased excitability is long-term potentiation (LTP). 
It has first been described in the hippocampus (Bliss and Lomo, 1973), where it is generally 
believed to be a cellular correlate of learning and memory. LTP does also occur at synapses 
between C fibers and lamina I spinobrachial projection neurons (Randic et al., 1993; Liu and 
Sandkuhler, 1995; Sandkuhler and Liu, 1998; Ikeda et al., 2003; Sandkuhler, 2007). In 
contrast to hippocampal LTP, C fiber-induced LTP in the dorsal horn can be elicited by 
stimulation frequencies as low as 1-2 Hz, i.e. at frequencies occurring naturally in C fibers 
during physiological activation (Drdla and Sandkuhler, 2008). A long-lasting increase in the 
efficacy of synaptic transmission between C fiber nociceptors and spinal projection neurons 
very likely contributes to enhanced pain sensitivity following intense nociceptive input to the 
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spinal cord. It can hence explain the long-lasting hyperalgesia observed in chronic pain 
patients.  
However, other symptoms of chronic pain in particular allodynia cannot easily be explained 
through such processes. Allodynia (or touch-evoked pain) is by definition a form of pain 
which is triggered by activation of non-nociceptive (low-threshold) Aβ mechanoreceptive 
fibers. One concept explains allodynia through a suprathreshold activation of normally “pain-
specific” projection neurons via polysynaptic connections formed by Aβ fibers and excitatory 
interneurons. Under healthy conditions, this pathway is silent, but can become active under 
conditions of reduced GABAergic or glycinergic synaptic inhibition (see also figure 4). 
1.2.3 Diminished Synaptic GABAergic and Glycinergic Control 
Already in 1965, the gate control theory of pain (Melzack and Wall, 1965) attributed to 
inhibitory interneurons located in the superficial dorsal horn a critical role in sensory and 
nociceptive processing, and proposed that these neurons would determine whether 
nociceptive input coming from the periphery was transmitted through the spinal cord to 
higher CNS areas where pain becomes conscious.  
Histological experiments have later confirmed the existence of different inhibitory 
interneurons in the spinal dorsal horn. Studies using antisera against GABA and glycine 
demonstrated the presence of inhibitory interneurons throughout the grey matter of the spinal 
dorsal horn. In its superficial layers, about 30% of lamina I and II neurons exhibit GABA-like 
immunoreactivity (Todd and Sullivan, 1990). Many of these GABAergic neurons (33, 43% in 
lamina I, II, respectively) are also immunoreactive for glycine. This is supported by more 
recent experiments that employed genetically modified mice expressing enhanced green 
fluorescent protein (EGFP) under the transcriptional control of the glutamic acid 
decarboxylase (GAD)67 (gad1) gene, a marker gene for GABAergic neurons (Oliva et al., 
2000; Tamamaki et al., 2003). Coronal sections of spinal cords from these mice show 
numerous EGFP labeled neurons in lamina I-III and around the central canal but only few 
neurons in the deeper dorsal horn. Glycinergic neurons tagged with EGFP expressed under 
the control of the GlyT2 promotor gene show a somewhat different distribution (Zeilhofer, 
2005) with a high abundance of these neurons in the deeper laminae (laminae III-V) and 
relatively few neurons in laminae I and II. 
The inhibitory action of GABA appears to be more complex in the spinal dorsal horn than in 
most parts of the brain, where GABA inhibits neuronal excitability primarily through 
hyperpolarization and the activation of a shunting conductance. At the level of the spinal 
cord, GABAA receptors are expressed not only postsynaptically on dorsal horn neurons, but 
are also found at the spinal terminals of primary afferent nerve fibers where they contribute to 
presynaptic inhibition through primary afferent depolarization (PAD) (Eccles et al., 1961). In 
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contrast to adult central neurons (including postsynaptic dorsal horn neurons), which are 
hyperpolarized by GABA, primary sensory neurons including their spinal terminals are 
usually depolarized due to an unusually high intracellular chloride concentration. This 
depolarization originates from a very particular expression pattern of chloride transporters 
with high expression of NKCC1, which transports chloride, sodium and potassium into the 
cell (Sung et al., 2000; Price et al., 2006), and low expression of KCC2 (Rivera et al., 1999), 
which transports chloride and potassium out of the cell. Subthreshold primary afferent 
depolarization (PAD) causes presynaptic inhibition, which reduces transmitter release from 
primary afferent nerve terminals possibly through inactivation of voltage-gated Ca2+ 
channels, or through activation of a shunting conductance in the intraspinal segment of the 
incoming axon, which would interfere with the propagation of the incoming action potentials. 
It is believed that primary afferent depolarizations can become suprathreshold under 
pathological conditions and would then facilitate nociception (Willis, 1999). Figure 4 
summarizes current concepts of the integration of inhibitory GABAergic and glycinergic 
neurons in the dorsal horn neuronal circuit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Distribution of GABAergic and glycinergic neurons. 
 
Transverse sections of the lumbar spinal cord of GAD67-EGFP (Tamamaki et al., 2003) and GlyT2-
EGFP (Zeilhofer, 2005) transgenic mice at different magnification. GAD67-EGFP tagged somata are 
most prominent in lamina II, whereas GlyT2-EGFP positive somata are most abundant in the deeper 
dorsal horn (lamina III and V). Scale bars: 100 μm and 50 μm, top and bottom panels, respectively. 
Adapted from (Zeilhofer et al., 2009). 
 
A critical role of the two inhibitory neurotransmitters GABA and glycine in the spinal control of 
nociception was confirmed in behavioral experiments when several groups tested the effects 
of spinally applied bicuculline and strychnine, blockers of GABAA and glycine receptors, on 
nociceptive behavior in rodents (Roberts et al., 1986; Yaksh, 1989; Yamamoto and Yaksh, 
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1993; Sivilotti and Woolf, 1994; Malan et al., 2002). It was found that both antagonists 
increased nociceptive reactions elicited by exposure to noxious stimuli and induced 
nociceptive reactions in response to innocuous stimuli such as light touch. The spinal 
pharmacological antagonism of GABAA and glycine receptors with bicuculline or strychnine 
thus induces typical symptoms of chronic pain such as tactile allodynia and hyperalgesia. 
Conversely, intrathecal application of GABA reversed thermal and mechanical sensitivity in 
rats with chronic constriction nerve injury (Eaton et al., 1999). Most importantly, it has 
recently been demonstrated that a loss of inhibitory pain control occurs also endogenously in 
the natural course of inflammatory and neuropathic pain and after intense nociceptive input 
up te spinal dorsal horn. Diminished inhibitory pain control at the spinal dorsal horn level may 
thus constitue a major factor in the generation and maintenance of central pain sensitization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Possible integration of inhibitory dorsal horn neurons in spinal pain processing 
circuits. 
 
GABAergic islet cells (yellow) in the substantia gelatinosa (L II) receive monosynaptic input from C 
fibers, which are believed to be mainly non-nociceptive touch-sensitive (Bennett et al., 1980). These 
lamina II GABAergic cells form different synaptic connections, with presynaptic terminals of primary 
afferent fibers, where they induce primary afferent depolarization, and with intrinsic superficial dorsal 
horn neurons, where they cause classical postsynaptic inhibition. They probably also synapse to 
lamina I (L I) projection neurons. Mixed GABA/glycinergic cells (green) and pure glycinergic cells are 
located mainly in the deeper laminae (L III and V). They are probably excited primarily by 
mechanosensitive fibers and cause postsynaptic inhibition of excitatory interneurons and possibly also 
of projection neurons. Removal of this inhibition leads to polysynaptic excitation of normally 
nociceptive specific neurons in lamina I and induces touch-evoked pain (allodynia). Excitatory neurons 
and terminals (red). Adapted from (Zeilhofer et al., 2009). 
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Synaptic Dis-inhibition in Inflammatory Pain 
Peripheral inflammation induces a pronounced increase in the spinal production of 
prostaglandin E2 (PGE2), a key mediator of central inflammatory hyperalgesia. The two 
enzymes required for inflammation-induced PGE2 production, cyclooxygenase-2 (COX-2) 
and inducible microsomal prostaglandin E synthase 1 (mPGES-1), are up-regulated in the 
dorsal horn within hours after induction of peripheral inflammation (Beiche et al., 1996; 
Murakami et al., 2000; Samad et al., 2001; Claveau et al., 2003). A major down-stream effect 
of spinally produced PGE2 is the reduction of glycinergic transmission in the superficial 
dorsal horn (Ahmadi et al., 2002). This inhibition occurs through a postsynaptic mechanism 
involving the activation of PGE2 receptors of the EP2 subtype, subsequent cAMP production 
and activation of protein kinase A (PKA). Activated PKA phosphorylates and inhibits a 
specific isoform of gylcine receptors containing the α3 subunit, which in the spinal cord is 
distinctly expressed in the superficial layers (Harvey et al., 2004). Interestingly, PGE2 
mediated inhibition of glycine receptors occurs in the majority of excitatory superficial dorsal 
horn neurons (Ahmadi et al., 2002; Reinold et al., 2005), in a pattern which is reminiscent of 
the PKCγ activation seen in vivo after blockade of glycine receptors with strychnine 
(Miraucourt et al., 2007). Work in EP2-receptor-deficient mice and in mice lacking the glycine 
receptor α3 (GlyRα3) subunit has shown that the pro-nociceptive actions of PGE2 are 
virtually absent in these mice and that inflammatory pain is strongly reduced (Harvey et al., 
2004; Reinold et al., 2005). Interestingly, the development of neuropathic pain in chronic 
constriction injury (CCI) model is not altered in EP2 or GlyRα3 deficient mice as compared to 
wild type mice (Hosl et al., 2006). A similar pattern has been reported earlier in mice carrying 
a null mutation in the regulatory subunit of neuronal protein kinase A (Malmberg et al., 1997). 
These mice also showed reduced nociceptive responses to intrathecal PGE2, but exhibited 
normal pain responses in the CCI model. 
It should be noted that inflammation can also up-regulate GABAergic inhibition in the spinal 
dorsal horn through production of endogenous 3α5α-neurosteroids (Inquimbert et al., 2007). 
These neurosteroids are positive allosteric modulators of GABAA receptors (Hosie et al., 
2006), which, at least in the spinal dorsal horn, target primarily extrasynaptic GABAA 
receptors (Mitchell et al., 2007). They are regularly produced in the spinal cord during 
development, but are normally absent in the adult (Keller et al., 2004). In response to a 
peripheral inflammatory stimulus, they re-appear in the spinal cord and may limit 
inflammatory thermal hyperalgesia (Poisbeau et al., 2005; Vergnano et al., 2007). 
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Synaptic Dis-inhibition in Neuropathic Pain 
At least two mechanisms have been proposed that would cause synaptic dis-inhibition after 
peripheral nerve injury. The group of Clifford Woolf proposed that GABAergic synaptic 
transmission was diminished in spinal cord slices of neuropathic rats (Moore et al., 2002) 
This loss was accompanied by a reduction in GAD65 immunoreactivity in the dorsal horn 
ipsilateral to the peripheral nerve injury. Whether or not this loss is due to an apoptotic death 
of GABAergic interneurons, as suggest by the authors, is still controversial (Polgar et al., 
2005; Scholz et al., 2005; Polgar and Todd, 2008). Since GAD antisera mainly stain 
presynaptic boutons (Mackie et al., 2003), it is conceivable that only GABAergic boutons 
degenerate, while their neuronal somata remain intact. 
Another pathway leading to diminished synaptic inhibition depends on the activation of spinal 
micoglia, which has been recognized as a key event in the generation of neuropathic pain 
following peripheral nerve damage (Tsuda et al., 2003; Scholz and Woolf, 2007). A possible 
link between microglia activation and altered neuronal processing of sensory information is 
the release of brain-derived neurotrophic factor (BDNF) from microglia cells and the 
subsequent trkB-mediated down-regulation of the potassium chloride co-transporter KCC2 in 
dorsal horn neurons (Coull et al., 2003; Coull et al., 2005). KCC-2 is required for the 
maintenance of a low intracellular chloride concentration (Rivera et al., 1999) and reduced 
expression of KCC2 increases intracellular chloride concentrations and renders GABAergic 
and glycinergic input less inhibitory, or may even turn it into excitation.  
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A       B 
 
Figure 5. Diminished synaptic GABAergic and glycinergic control. 
 
(A) Dis-inhibition in inflammatory pain states. Cyclooxygenase-2 (COX-2) and microsomal 
prostaglandin E synthase (mPGES1) become induced in the spinal cord in response to inflammation 
in peripheral tissues and produce PGE2. PGE2 binds to PGE2 receptors of the EP2 subtype, which 
increase cAMP levels and activate protein kinase A (PKA). PKA then phosphorylates and inhibits a 
specific subtype of glycine receptors containing the α3 subunit, which normally control the excitability 
of superficial dorsal horn neurons. This dis-inhibition facilitates the firing of these neurons and 
promotes transmission of nociceptive signals through the spinal cord to higher brain areas where pain 
becomes conscious. (B) Dis-inhibition in neuropathic pain states. Spinal microglia activated in 
response to peripheral nerve damage, releases brain-derived neurotrophic factor (BDNF). BDNF 
subsequently down-regulates the potassium-chloride cotransporter (KCC-2), which normally keeps 
intracellular chloride concentration ([Cl−]i) low. This down-regulation reduces the inhibitory action of 
GABAA and glycine receptors. In some neurons GABAergic and glycinergic inhibition may become 
even depolarizing and excitatory. This dis-inhibition promotes the firing of dorsal horn neurons and the 
transmission of nociceptive signals. Adapted from (Zeilhofer and Zeilhofer, 2008). 
 
 
Synaptic Dis-inhibition in Activity-Dependent Sensitization 
A loss of dorsal horn synaptic inhibition can also occur in the absence of inflammation and 
nerve injury. Selective activation of C fiber nociceptors with capsaicin induces mechanical 
and thermal hyperalgesia at the site of injection (primary hyperalgesia) and in addition an 
exclusively mechanical sensitization (pin-prick hyperalgesia and touch-evoked pain) in a 
surrounding healthy skin area (Treede and Magerl, 2000). Plenty of evidence suggests that 
this secondary hyperalgesia is of central (spinal) origin (Woolf, 1983), and involves 
diminished synaptic inhibition (Sivilotti and Woolf, 1994). It has recently been demonstrated 
by our goup (Pernia-Andrade et al., 2009) that intense C fiber input reduces the release of 
GABA and glyine from inhibitory dorsal horn neurons through the production of 
endocannabinoids and the subsequent activation of CB1 cannabinoid receptors on inhibitory 
axon terminals.  
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1.3 GABA Receptors 
GABA receptors are activated by the neurotransmitter GABA, the major inhibitory 
neurotransmitter in the vertebrate central nervous system. GABAA receptors are ligand-gated 
ion channels (also known as ionotropic receptors) permeable to chloride and bicarbonate, 
whereas GABAB receptors are G protein-coupled or metabotropic receptors. GABAA 
receptors inhibit neuronal activation through hyperpolarization and the activation of a 
shunting conductance. GABAB receptors were originally distinguished from GABAA receptors 
on the basis of their pharmacological properties (Bowery et al., 1980). They reduce neuronal 
excitability through the opening of inwardly rectifying K+ channels and the inhibition of 
voltage-gated calcium channels (VGCCs). They also inhibit adenylyl cyclases (Pan et al., 
2008). A subclass of ionotropic GABAA receptors, insensitive to bicuculline and exclusively 
composed of ρ subunits (Shimada et al., 1992; Kusama et al., 1993b; Kusama et al., 1993a), 
has originally been designated as GABAC receptors but is now termed GABAA-ρ (Olsen and 
Sieghart, 2008).  
1.3.1 GABAA Receptors 
GABAA receptors are members of the Cys-loop ligand-gated ion channel superfamily 
(Mohler, 2006), which includes nicotinic acetylcholine receptors, GABAA receptors, glycine 
and 5-HT3 receptors. This ion channel family is characterized by the presence of an 
extracellular loop formed by a disulfide bond between two cysteine residues. GABAA 
receptors are heteropentameric ion channels assembled from a repertoir of at least 19 
subunits (α1-6, β1-3, γ1-3, δ, ε, θ, π, ρ1-3). The most common subtype in the CNS is composed of 
two α, two β, and one γ subunit (Mohler, 2006). The receptor is activated upon binding of two 
GABA molecules, at an interface formed by an α and a β subunit for each molecule (Mohler, 
2006). Activation of GABAA receptors by GABA and other agonists (e.g. muscimol) leads to 
an increase in chloride conductance driving the membrane potential towards the chloride 
equilibrium potential which is about -65 mV in most adult central neurons, thereby decreasing 
the excitability of the neuron. There are also reports of excitatory effects of GABAA receptor 
activation, which occur as a consequence of increased intracellular cloride concentrations 
present e.g. during development (Ben-Ari et al., 1997; Taketo and Yoshioka, 2000) or in 
certain cell populations, such as some hippocampal interneurons (Lamsa and Taira, 2003) 
or, as discussed above, in DRG neurons (see 1.2.3).  
GABAA receptors contain several allosteric binding sites, which modulate their activity. These 
allosteric sites are the targets of various drugs, including benzodiazepines, barbiturates, 
ethanol, neuroactive steroids, inhaled anaesthetics, and others (Mohler, 2006). GABAA 
receptors containing the α1, α2, α3 or α5 subunit associated with a γ2 subunit are 
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benzodiazepine-sensitive (Wieland et al., 1992). Once benzodiazepines have bound, they 
lock the GABAA receptor into a conformation that increases the affinity for GABA, and the 
frequency of channel openings. Benzodiazepines also potentiate the effect of muscimol, 
another GABAA receptor agonist, on GABAA receptors (Akhondzadeh and Stone, 1998; 
Akhondzadeh et al., 2002). A minority of GABAA receptors contains instead α4, α6, or ρ-
subunits and is insensitive to classical benzodiazepines (1H-Benzo-1,4-diazepine). Some of 
these receptors are however subject to modulation by other drugs such as neurosteroids 
(Lambert et al., 2003; Belelli and Lambert, 2005; Belelli et al., 2006) and ethanol (Kumar et 
al., 2009). 
 
 
Figure 6. Benzodiazepine-sensitive GABAA receptor.  
 
Schematic illustration of a GABAA receptor protein ((α1)2(β2)2(γ2)) which illustrates the five combined 
subunits that form the protein, the chloride (Cl-) ion channel pore, the two GABA active binding sites at 
the α1 and β2 interfaces, and the benzodiazepine (BDZ) allosteric binding-site at the α1 and γ2 
interface. 
 
1.4 Analysis of GABAA Receptor Functions Using Genetically Modified 
Mice 
In the last decade, many efforts have been made to study the functions of specific GABAA 
receptor isoforms in vivo with knock-out mice which lack different GABAA receptor subunits. 
In many of these knock-out mice, compensatory up- or down-regulations of other GABAA 
receptor subunits (α1 knock-out, (Sur et al., 2001; Vicini et al., 2001) limit the interpretation 
of these studies. Other knock-out lines such as the γ2 knock-out (Gunther et al., 1995), 
exhibited lethal phenotypes. In contrast, the β2 knock-out had no obvious behavioral 
consequences (Sur et al., 2001) although the β2 subunit is the most abundant of all β 
subunits.  
Important insights into the understanding of the contribution of GABAA receptor isoforms to 
the different in vivo actions of benzodiazepines came from the generation of GABAA receptor 
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point-mutated (“knock-in”) mice, which carry GABAA receptor α subunits rendered 
benzodiazepine-insensitive through the exchange of a single amino acid (Rudolph et al., 
2001). Knock-in mice containing these point-mutations (α1(H101R), α2(H101R), α3(H126R), 
α5(H105R) (Rudolph et al., 1999; Low et al., 2000; Crestani et al., 2001; Crestani et al., 
2002) were generated to characterize the involment of defined GABAA receptor 
benzodiazepine-sensitive α subtypes in different actions of diazepam. Most importantly, it 
has been found that diazepam-induced sedation and anterograde amnesia are mediated 
through α1-containg GABAA receptors (Rudolph et al., 1999; McKernan et al., 2000), while 
the α2 subunit is required for the anxiolytic (Low et al., 2000) and myorelaxing effects 
(Crestani et al., 2001) of benzodiazepines. α5 subunits seem to be involved in learning and 
memory (Crestani et al., 2002). With the exception of the α5(H105R) mice, the three other α 
subunit knock-in mouse lines did not show a decrease in the mutated subunit or apparent 
compensatory up- or down-regulation of other GABAA receptor subunits. 
1.5 Conditional Gene Deletion Using the cre/loxP System 
The global knock-out of certain genes can lead to embryonic lethality, thus making it 
impossible to obtain adult animals for the analysis of the gene function in vivo. The cre/loxP 
recombination provides a special type of site-specific gene recombination (Sauer et al., 1987; 
Sauer and Henderson, 1988a, 1988b). creloxP recombination involves the targeting of a 
specific sequence of DNA and its splicing with the help of an enzyme called cre 
recombinase. The cre recombinase is a 38-kDa protein that recognizes a 34-bp DNA 
segment termed “locus of crossing-over of P1” (loxP). It has first been discovered in the 
bacteriophage P1 (Orban et al., 1992; Lakso et al., 1996). This minimal target sequence site 
is unlikely to occur randomly in the mouse genome and is small enough to be "neutral" when 
integrated into chromosomal DNA. If two loxP sites are located on the same DNA molecule, 
cre causes inversion or excision of the intervening DNA segment depending on their 
respective orientation. Two transgenic mouse lines are required to generate tissue-specific 
gene deletions. The first mouse line expresses the cre recombinase under the control of a 
tissue-specific promoter. The second carries loxP sites around the gene (essential exon) of 
interest ("floxed gene"). In co-transgenic offspring, the gene (or exons) of interest will be 
removed selectively from cells expressing cre recombinase. The cre recombinase can also 
be expressed in a temporally controlled manner. CreERT2 encodes a cre recombinase fused 
to a mutant estrogen ligand-binding domain (ERT2) that requires the presence of tamoxifen 
for activity.  
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2. Aims 
 
As outlined above, several lines of evidence suggest that pathological pain of inflammatory 
or neuropathic origin converge onto a loss of synaptic inhibition in the spinal dorsal horn. A 
potentiation of inhibitory neurotransmission should in principle allow compensating for this 
loss. Benzodiazepines, which facilitate the action of GABA at GABAA receptors exert clear 
analgesic or antihyperalgesic actions after local spinal application, both in animal models of 
pain (Clavier et al., 1992; Sumida et al., 1995) and in patients (Tucker et al., 2004a; Tucker 
et al., 2004b), for a comprehensive review see (Jasmin et al., 2004). This thesis uses an 
integrative approach combining pharmacological, behavioral, electrophysiological and 
morphological experiments in wild type and genetically modified mice to unravel the identity 
and the localization of the GABAA receptor subtypes mediating this analgesia.  
2.1 Identification of GABAA Receptor Isoforms Mediating 
Benzodiazepine-Induced Spinal Analgesia 
This aim was achieved with behavioral tests in wild type and GABAA receptor mutant mice 
carrying point mutated (diazepam-insensitive) α subunits (α1, α2, α3, α5) (Rudolph et al., 
1999; Low et al., 2000; Crestani et al., 2001; Crestani et al., 2002). The effect of intrathecally 
applied diazepam was tested in models of inflammatory, neuropathic and chemically-induced 
pain. The results from these mutant mouse studies were complemented with experiments 
employing subtype-specific benzodiazepine binding-site ligands. 
2.2 Identification of the Contribution of Presynaptic GABAA Receptors 
Located on the Central Terminals of Primary Nociceptive Afferents to the 
Spinal Control of Nociception 
At the spinal cord level, GABAA receptors can in principle modulate nociceptive processing 
via at least two sites. Postsynaptically located GABAA receptors directly reduce the 
excitability of central dorsal horn neurons, while GABAA receptors located presynaptically on 
the spinal terminals of primary afferent nociceptors cause presynaptic inhibition. 
Morphological data employing immunofluorescence and in-situ hybridization have suggested 
that α2-GABAA receptors, which mediate most of the analgesic effects of spinal 
benzodiazepines (Knabl et al., 2008), are the major if not the only GABAA receptor isoform in 
dorsal root ganglion neurons (Ma et al., 1993). To address the contribution of these 
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presynaptic GABAA receptors to the spinal control of nociception and to the analgesic effects 
of spinal benzodiazepines, mice were generated which carry targeted deletions/mutations of 
the GABAA receptor α2 subunit in primary nociceptive neurons. Behavioral experiments were 
done to analyze the phenotype of GABAA receptor mutant mice in different models of 
inflammatory and neuropathic pain in absence of treatment and after intrathecal injection of 
diazepam. 
2.3 Generation of a cre Transgenic Mouse Line for Brain-Sparing 
Conditional Gene Deletion 
This project part aimed at the generation of a cre transgenic mouse for brain-sparing gene 
deletion, which would allow to determine the contribution of spinal versus supraspinal GABAA 
receptors to benzodiazepine-induced analgesia. To address this aim, it was planned to 
express the cre recombinase under the transcriptional control of the homeobox gene Hoxb8, 
which is expressed during development throughout the spinal cord up to cervical segment 
C4. Proper expression of the transgene should be verified in morphological experiments 
performed on tissue from co-transgenic offspring of cre transgenic mice crossed with 
different reporter strains (Rosa26lacZ and RA/EG).  
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3. Results 
3.1 Reversal of Pathological Pain through Specific Spinal GABAA 
Receptor Subtypes* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Knabl J, Witschi R, Hösl K, Reinold H, Zeilhofer U, Ahmadi S, Brockhaus J, Sergejeva M, 
Hess A, Brune K, Fritschy JM, Rudolph U, Möhler H, Zeilhofer HU (2008): Reversal of 
pathological pain through specific spinal GABAA receptor subtypes. Nature 451, 330-334. 
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Abstract 
Inflammatory diseases and neuropathic insults are frequently accompanied by severe and 
debilitating pain, which can become chronic and often unresponsive to conventional 
analgesic treatment1,2. A loss of synaptic inhibition in the spinal dorsal horn is considered to 
contribute significantly to this pain pathology3–7. Facilitation of spinal γ-aminobutyric acid 
(GABA)ergic neurotransmission through modulation of GABAA receptors should be able to 
compensate for this loss8,9. With the use of GABAA receptor point-mutated knock-in mice in 
which specific GABAA receptor subtypes have been selectively rendered insensitive to 
benzodiazepine-site ligands10–12, we show here that pronounced analgesia can be achieved 
by specifically targeting spinal GABAA receptors containing the α2 and/or α3 subunits. We 
show that their selective activation by the non-sedative (‘α1-sparing’) benzodiazepine-site 
ligand L-838,417 (ref. 13) is highly effective against inflammatory and neuropathic pain yet 
devoid of unwanted sedation, motor impairment and tolerance development. L-838,417 not 
only diminished the nociceptive input to the brain but also reduced the activity of brain areas 
related to the associative-emotional components of pain, as shown by functional magnetic 
resonance imaging in rats. These results provide a rational basis for the development of 
subtype-selective GABAergic drugs for the treatment of chronic pain, which is often 
refractory to classical analgesics. 
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Introduction 
More than 40 years ago, the gate control theory of pain14 proposed that inhibitory neurons in 
the superficial dorsal horn of the spinal cord control the relay of nociceptive signals (that is, 
those evoked by painful stimuli) from the periphery to higher areas of the central nervous 
system. The pivotal role of inhibitory GABAergic and glycinergic neurons in this process has 
recently been demonstrated in several reports indicating that a loss of inhibitory 
neurotransmission underlies several forms of chronic pain3–7. Despite this knowledge, 
inhibitory neurotransmitter receptors have rarely been considered as targets for analgesic 
treatment. In fact, classical benzodiazepines, which are routinely used for their sedative, 
anxiolytic and anticonvulsant activity, largely lack clear analgesic efficacy in humans when 
given systemically15. To address this obvious discrepancy we investigated the molecular 
basis of GABAergic pain control in the spinal cord in an integrative approach based on an 
electrophysiological and behavioural analysis of genetically modified mice and on functional 
imaging in rats. 
 
Methods  
Mice and rats. Behavioural experiments were performed in male and female 7–12-week-old 
mice or in male 7–12-week-old Wistar rats. Wild-type mice and GABAA receptor mutant mice 
(α1(H101R), α2(H101R), α3(H126R) and α5(H105R))10–12 were maintained on a 129X1/SvJ 
background. In all behavioural tests, the observer was blinded to the genotype or to the drug 
treatment. Permission for the animal experiments was obtained from the Regierung von 
Mittelfranken (ref. no. 612-2531.31-17/03) and from the Veterinäramt des Kantons Zürich 
(ref. no. 121/2006 and 34/2007).  
 
Drugs. For intrathecal injection in mice, diazepam was dissolved in 10% dimethyl sulphoxide 
(DMSO), 90% artificial cerebrospinal fluid (ACSF) (vehicle). Total intrathecal injection volume 
was 5 μl (for details of the injection procedure see ref. 31). Up to a concentration of 20%, 
intrathecal DMSO had no effect on pain behaviour in mice. For i.p. injection, diazepam was 
dissolved in 0.3% Tween 80, 99.7% ACSF. Morphine was dissolved in ACSF. L-838,417 
synthesized by Anawa was suspended in 0.5% methylcellulose and 0.9% NaCl and was 
applied to rats either orally or i.p. in a total volume of 200 μl. Flumazenil (10 mg·kg-1) and 
naloxone (10 mg·kg-1) were dissolved in DMSO (1%) and injected i.p. in a total volume of 
200 μl. 
 
Formalin test. Formalin (5%, 20 μl) was injected subcutaneously into the dorsal surface of 
the left hindpaw32. Flinches of the injected paw were counted for 60 min starting immediately 
RESULTS (paper 1) 
- 28 - 
after formalin injection. Intrathecal drugs (diazepam or vehicle) were injected 10 min before 
formalin injection. Flumazenil (10 mg·kg-1) was injected i.p. 30 min before formalin injection.  
 
Inflammatory pain. Inflammatory pain was assessed in the zymosan A model33. In mice, 
0.06 mg of zymosan A suspended in 20 μl of 0.9% NaCl was injected subcutaneously into 
the plantar side of the left hindpaw. The model was also used in rats, but 1 mg of zymosan A 
was used. Heat hyperalgesia was assessed 24 h and 6 h after induction of inflammation in 
mice and rats, respectively.  
 
Neuropathic pain. Diazepam, L-838,417 and morphine were analysed in the CCI model34 in 
7–12-week-old mice or rats. Unilateral constriction injury of the left sciatic nerve just proximal 
to the trifurcation was performed with three loose ligatures. In sham-operated animals the 
sciatic nerve was exposed and the connective tissue was freed, but no ligatures were 
applied. In these sham-operated animals only a minor and transient hyperalgesia occurred. 
Heat hyperalgesia, cold allodynia and mechanical sensitization were assessed 7–9 days 
after surgery.  
 
Heat hyperalgesia. Paw withdrawal latencies on exposure to a defined radiant heat stimulus 
were measured with a commercially available apparatus (Plantar Test; Ugo Basile). Four or 
five measurements were taken in each animal for every time point. Measurements of paw 
withdrawal latencies of the inflamed or injured paw and of the contralateral paw were made 
alternately. 
 
Cold allodynia. The time spent lifting, shaking or licking the paw (seconds per minute) was 
measured for 5 min after application of a drop of acetone onto theaffected paw. 
 
Mechanical sensitization. Mechanical sensitivity was assessed with electronic von Frey 
filaments (IITC). Triple measurements of paw withdrawal thresholds (g) were made for each 
time point and animal. 
 
Locomotor activity. Locomotor activity was tested with a commercially available 
microprocessor-controlled activity cage (Actiframe; Gerb Elektronik). Mice were placed in the 
apparatus 15 min before testing. Motor activity was measured 10–30 min and 40–80 min 
after intrathecal and oral drug application, respectively. 
 
Motor impairment. A possible impairment of motor function was assessed with the rotarod 
test35. Rats were trained on day zero and the maximum speed tolerated for at least 2 min 
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was determined for each rat. On the following day, rotarod performance was determined 
again 30 min after treatment with L-838,417 or vehicle (administered orally). 
 
Electrophysiology. DRGs (from segments L4–L6) were removed from 14–24-day-old mice, 
dissociated and plated on poly-(L-lysine)-coated cover slips (for details see ref. 36). GABA-
induced currents were recorded from capsaicin sensitive DRG neurons 3–30 h after plating. 
Transverse slices (250 μm thick) of the lumbar spinal cord were prepared from 14–24-day-
old mice. GABAergic membrane currents were recorded from superficial dorsal horn neurons 
(laminae I and II) as described previously3. In both preparations, GABA (1 mM) was applied 
by short (10 ms) puffer applications to the soma of the recorded neuron at a frequency of 
0.07 Hz. Diazepam (1 μM) was applied by means of bath perfusion. All recordings were 
made in the presence of the GABAB receptor antagonist CGP-55,845 (200 μM). 
 
Immunofluorescence. The localization of GABAA receptor α subunits on primary afferent 
nerve terminals and intrinsic dorsal horn neurons was determined by double 
immunofluorescence staining on sections from perfusion-fixed adult mice27. Antibodies were 
home-made subunit-specific antisera27 and commercial antibodies against substance P 
(T1609; Bachem) and NK1 (S8305; Sigma). Sections processed for double 
immunofluorescence were digitalized by confocal laser scanning microscopy (resolution 90 
nm per pixel; two or three images per animal; n = 3 mice) and images were processed with 
Imaris (Bitplane). Double labeled objects (image profiles) in single confocal sections were 
identified by a segmentation algorithm (minimal size 0.2 μm2; minimum intensity 50–90 on a 
256-grey-level scale). The numbers of single-labelled and double-labelled profiles were 
calculated. All values are expressed as percentages of double-labelled profiles relative to the 
marker indicated. 
 
Functional magnetic resonance imaging. fMRI experiments were performed in male 
Wistar rats weighing 350–400 g. During the measurements, rats were slightly anaesthetized 
with isoflurane (1–2 %) to maintain a respiration rate of about 60 c.p.m. and constant blood 
pCO2 levels. Measurements were made with a Bruker 4.7-T Biospec scanner with a free 
bore of 40 cm, equipped with an actively radio frequency decoupled coil system. A whole-
body birdcage resonator enabled homogenous excitation, and a 3-cm quadrature surface 
coil, which served as a receiver, was located directly above the head of the animal to 
maximize the signal-to-noise ratio. Constant positioning of the rat’s head within the scanner 
was verified by rapid acquisition of magnetic resonance images at 200-ms intervals. A 
functional series of 1,470 sets (4 s each, total of 96 min) of 22 axial images (slice thickness 1 
mm, field of view 25 X 25 mm2, 5.20 to -14.60 mm from the bregma37) were acquired with the 
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echo planar imaging technique (EPI: matrix 64 X 64, TR= 4,000 ms, TEef = 23.4 ms, two 
acquisitions). Anatomical scans with a high spatial resolution were obtained with RARE38 
(slice thickness 1 mm, field of view 25 X 25 mm2, matrix 256 X 256, TR = 400 ms, TE = 18 
ms, NEX = 8). Noxious heat stimulation was performed by applying temperature ramps (34–
52 °C (noxious stimulation) or 34–42 °C (innocuous stimulation) with 15-s rise and fall times 
and a 5-s plateau phase) through two Peltier elements tightly attached to both hind paws (in 
awake rats this stimulation method yielded paw withdrawal latencies similar to those 
obtained in the behavioural tests with radiant heat). Thermal stimuli were applied to the left 
and right hind paw alternately at 2-min intervals. After 32 min of recording, L-838,417 (1 
mg·kg-1) or vehicle was injected through an i.p. catheter without changing the position of the 
animal in the scanner. After drug injection, recording was continued for 64 min with the same 
stimulation method. Data were analysed with Brain voyager QX after appropriate 
preprocessing (motion correction, mean intensity adjustment, spatial smoothing 0.6 mm full-
width at half-maximum, temporal gaussian smoothing 12 s, and temporal high-pass filtering 
of nine cycles) with a General Linear Modelling approach with four predictors: inflamed 
(left)/non-inflamed (right) paw before and after drug injection and Bonferroni correction. z-
score maps of the individual rats weregroup analysed with custom-made analysis software 
(MagnAn39 running under IDL). Anatomical and functional images were transferred into the 
register by an affine transformation scheme with only six degrees of freedom derived from 
the individual brain masks. The registered anatomical data and z-score maps were averaged 
over all animals. Contrast-specific mean z-score maps were calculated using a threshold of 
3.0. Significantly activated voxels were labelled automatically with a digital standard rat brain 
atlas37. For each rat, brain structure and stimulation condition, we then first calculated the 
activation intensity as the stimulus-induced relative change in the BOLD signal (F). To 
quantify the effect of L-838,417 on the stimulus-induced BOLD signal changes we calculated 
ΔF/F as (Fpost - Fpre)/Fpre, where Fpost is the value of F after drug treatment and Fpre is the 
value before drug treatment. Statistical analysis was performed witht he paired Student t-test. 
False-colour images of stimulus-induced changes in BOLD signals were obtained by 
mapping the calculated mean BOLD signal change of each voxel onto all significantly 
activated voxels. Note that the different colours in Fig. 7 encode F (signal amplitude), not 
statistical coefficients. 
 
Results and Discussion 
We first tested whether benzodiazepines exert antinociceptive effects at the level of the 
spinal cord by employing the mouse formalin assay, a model of tonic chemically induced 
pain. When the classical benzodiazepine diazepam was injected intrathecally into the lumbar 
spinal canal at doses of 0.01–0.09 mg per kg body weight, an apparent dose-dependent and 
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reversible antinociception was obtained that could be antagonized by systemic treatment 
with the benzodiazepine antagonist flumazenil (10 mg·kg-1 intraperitoneally (i.p.)) (Fig. 1).  
 
 
 
Figure 1. Antinociceptive effects of diazepam (dzp) in the mouse formalin test. 
 
a, number of flinches (mean ± SEM, n = 5) versus time in wild-type (wt) mice treated with dzp 0.09 
mg/kg i.t. and/or flumazenil (flu, 10 mg/kg, i.p.). b, maximum possible analgesia (number flinches in 
dzp-treated mice / number flinches in vehicle-treated mice x 100%) (mean ± SEM) obtained with 
different doses of i.t. dzp. **, statistically significant against vehicle with P ≤ 0.01; ***, P ≤ 0.001 
(analysis of variance [ANOVA] followed by Bonferroni post hoc test). c, total number of flinches (mean 
± SEM). ***, statistically significant against all other groups (P ≤ 0.001, ANOVA followed by Bonferroni 
post-hoc test). 
 
We next sought to identify the GABAA receptor isoforms responsible for this antinociception. 
GABAA receptors are heteropentameric ion channels composed from a repertoire of up to 19 
subunits16. Benzodiazepine-sensitive isoforms are characterized by the presence of the γ2 
subunit and one of four α subunits (α1, α2, α3 or α5)17. The generation of four lines of 
GABAA-receptor point-mutated knock-in mice (α1(H101R), α2(H101R), α3(H126R) and 
α5(H105R)), in which a conserved histidine residue had been mutated to arginine, rendering 
the respective subunit insensitive to diazepam, has enabled the attribution of the different 
actions of diazepam to the individual GABAA receptor isoforms10–12. It also became possible 
to attribute the sedative effects of diazepam to GABAA receptors containing an α1 subunit10 
and the anxiolytic effect to those containing an α2 subunit11 or - at high receptor occupancy - 
an α3 subunit18. We then compared the antinociceptive efficacy of intrathecal diazepam (0.09 
mg·kg-1) in wild-type mice with that obtained in the four types of GABAA-receptor point-
mutated mice in models of inflammatory hyperalgesia induced by subcutaneous injection of 
zymosan A in to one hindpaw and of neuropathic pain evoked by chronic constriction of the 
left sciatic nerve (chronic constriction injury (CCI) model). Wild-type mice and all four types of 
mutant mice developed nearly identical pain sensitization after induction of inflammation or 
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peripheral nerve injury (Fig. 2a, c). In wild-type mice, intrathecal diazepam (0.09 mg·kg-1) 
reversibly reduced inflammatory heat hyperalgesia (Fig. 2b), as well as CCI-induced heat 
hyperalgesia (Fig. 2d), cold allodynia (Fig. 2e) and mechanical sensitization (Fig. 2f) by 82 ± 
13%, 92 ± 6% and 79 ± 9% (means ± s.e.m.), respectively. Responses of the non-inflamed 
or uninjured side were not significantly changed (Fig. 2a, c), indicating that spinal diazepam 
acted as an anti-hyperalgesic agent rather than as a general analgesic. Almost identical anti-
hyperalgesic effects to those in wild-type mice were seen in mice carrying diazepam-
insensitive α1 subunits. By contrast, α2(H101R) mice showed a pronounced reduction in 
diazepam-induced anti-hyperalgesia, which was consistently observed in all pain models 
tested. α3(H126R) and α5(H105R) mice showed smaller reductions, which occurred only in 
a subset of models. Importantly, intrathecal diazepam did not change spontaneous motor 
activity (Fig. 2g), indicating that the action of diazepam remained restricted to the spinal level 
and did not reach supra spinal sites, where sedation would have been induced. Anti-
hyperalgesic effects of spinal diazepam can in principle originate from the facilitation of 
GABAA receptors at different sites. Diazepam might act either on postsynaptic GABAA 
receptors located on intrinsic dorsal horn neurons, thereby increasing postsynaptic inhibition, 
or on GABAA receptors located on the central terminals of primary afferent nerve fibres to 
increase primary afferent depolarization and presynaptic inhibition19.  
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Figure 2. Antinociceptive effects of spinal diazepam in different mouse pain models.  
 
a, b, Inflammatory pain induced by subcutaneous injection of zymosan A into the left hindpaw in wild-
type (WT) mice and GABAA receptor point-mutated mice (α1(H101R), α2(H101R), α3(H126R), 
α5(H105R)). a, Paw withdrawal latencies (mean ± s.e.m.) in response to a defined radiant heat 
stimulus versus time after administration of intrathecal diazepam (D; 0.09 mg·kg-1; arrowed) 48 h after 
injection of zymosan A. V, vehicle. b, Percentage diazepam-induced analgesia in the different 
genotypes. c, d, As in a and b, but for the CCI model of neuropathic pain. e, f, Effects of intrathecal 
diazepam (0.09 mg·kg-1) on cold allodynia (e) and mechanical sensitivity (f) seven days after CCI 
surgery. Asterisk, P ≤ 0.05; two asterisks, P ≤ 0.01; three asterisks, P ≤ 0.001 (statistically significant 
against wild type; ANOVA followed by Bonferroni post-hoc test, n= 6 or 7 mice per group). g, Effects 
of diazepam (0.09 mg·kg-1 intrathecally, or 10 mg·kg-1  orally) on motor activity in the Actiframe test 
(mean ± s.e.m., n = 5 or 6), 10–30 min after intrathecal drug application or 40–80 min after oral drug 
application. Three asterisks, P ≤ 0.001 against vehicle (unpaired t-test). 
 
To identify the benzodiazepine-sensitive GABAA receptor isoforms expressed at these sites 
we first employed electrophysiological measurements. GABAergic membrane currents were 
recorded from superficial dorsal horn neurons in transverse slices of spinal cords and from 
acutely isolated primary afferent (dorsal root ganglion (DRG)) nociceptive neurons 
characterized by their sensitivity to capsaicin. In nociceptive DRG neurons obtained from 
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α2(H101R) mice, the facilitation of GABAergic membrane currents by diazepam was 
completely abolished, whereas no significant alteration was found in neurons from 
α1(H101R), α3(H126R) and α5(H105R) mice (Fig. 3a). Facilitation of GABAergic membrane 
currents by diazepam in intrinsic superficial dorsal horn (lamina I/II) neurons was significantly 
decreased in α2(H101R) and α3(H126R) mice but not in α1(H101R) or α5(H105R) mice 
(Fig. 3b). We next employed confocal immunofluorescence microscopy of dorsal horn 
GABAA receptor α subunits and studied their colocalization with substance P (a marker for 
primary peptidergic nociceptors) and for neurokinin 1 (NK1) receptors (a marker for intrinsic 
nociceptive dorsal horn neurons in lamina I). Consistent with our electrophysiological 
experiments and with previous morphological results in the rat20 was our observation that α2 
and α3 were the most abundant diazepam-sensitive GABAA receptor α subunits in the 
mouse spinal dorsal horn (Fig. 4).  
Co-staining experiments with antibodies against substance P or NK1 receptors (Fig. 3c–j and 
Table 1) revealed that α2, but not α1, α3 or α5, were extensively colocalized with substance-
P positive primary afferent terminals in lamina II, whereas colocalization with NK1-receptor-
positive lamina I neurons was greatest for the α3 subunit. Staining for α1 and α5 subunits 
was much less abundant and only occasionally colocalized with either substance P or NK1 
receptors. Both sets of experiments indicate that intrinsic dorsal horn neurons express mainly 
GABAA receptor isoforms containing α2 and α3 subunits, whereas α2 is the dominant 
diazepam-sensitive GABAA receptor α subunit in adult DRG neurons (see also ref. 21).  
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Figure 3. GABAA receptor α subunits in capsaicin-sensitive primary afferent DRG neurons and 
in intrinsic dorsal horn neurons.  
 
a, b, Potentiation of GABAergic membrane currents by diazepam in wildtype (WT) and GABAA 
receptor mutant mice. a, DRG neurons. Averaged membrane currents evoked by puffer-applied 
exogenous GABA (1 mM) and percentage potentiation (mean ± s.e.m.) by diazepam (1 μM, n= 5–9). 
Asterisk, P ≤ 0.05 (significant against all other genotypes; ANOVA followed by Fisher’s post-hoc test). 
b, Intrinsic superficial dorsal horn neurons (mean  s.e.m., n = 5–10). Asterisk, P ≤ 0.05 (significant 
against wild-type and α1(H101R); ANOVA followed by Fisher’s post-hoc test). c–j, Double 
immunofluorescence staining showing differential distribution of GABAA receptor α subunits (red) 
relative to substance P (SP)-positive axons and terminals (green) (c–f) or NK1 receptor-positive 
neurons (g–j) in laminae I and II. c, g, α1; d, h, α2; e, i, α3; f, j, α5. Arrows, double-labelled 
structures. Arrowheads, single-labelled structures devoid of GABAA receptor labelling. Scale bar, 5 μm 
(c–j). 
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Figure 4. Laminar distribution of GABAA receptor α subunits and of substance P (SP) and NK1  
receptor immunoreactivity. 
 
Single immunofluorescence staining for the GABAA receptor α1, α 2, α 3, α5 subunits, SP, and NK1 
receptors in lamina I and II of mouse lumbar spinal dorsal horn. a – d, distinct laminar distribution of 
GABAA receptor α subunits, illustrating the high relative abundance of α2 and α3 subunits. e, f, 
distribution of SP-positive primary afferent nerve fibers and NK1 receptor-positive neurons in the 
dorsal horn. Scale bar: 100 μm. 
 
 
Table 1: Quantitative assessment of GABAA receptor subunit colocalization with substance P 
(SP) and NK1 receptors 
markers α2-SP/α2 
α2α-SP/SP 
α3-SP/α3 
α3-SP/SP 
α2-NK1/α2 
α2-NK1/NK1 
α3-NK1/α3 
α3-NK1/NK1 
co-localization 37±8% 
47±13% 
19±5% 
24±5% 
9±3% 
27±6% 
21±4% 
47±9% 
 
 
The decrease in diazepam-induced anti-hyperalgesia in α2(H101R) and α3(H126R) mice 
corresponds well to the presence of these subunits on primary afferent nerve terminals 
and/or on intrinsic dorsal horn neurons. So far, our results indicated that the spinal 
antinociceptive effect of diazepam is mainly mediated by GABAA receptor isoforms 
containing the α2 and α3 subunits, whereas the activation of α1-containing GABAA receptors 
is not involved. We therefore tested whether a similar analgesic effect would also be 
achieved after systemic treatment with subtype-selective benzodiazepine-site agonists, 
which spare the α1 subunit, by employing the non-sedative benzodiazepine-site ligand L-
838,417, which is an antagonist at the α1 subunit and a partial agonist at receptors 
containing α2, α3 and α5 subunits13. Because L-838,417 possesses poor bioavailability and 
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an extremely short half-life in mice22, it was tested in rats. After systemic treatment, L-
838,417 produced dose-dependent and reversible anti-hyperalgesia in both the inflammatory 
and neuropathic pain models (Fig. 5). As expected, its maximum anti-hyperalgesic effect 
(Fig. 5a) was less than that of intrathecal diazepam, probably because L-838,417 exerts only 
partial agonistic activity. Anti-hyperalgesia was again completely reversed by flumazenil 
(10mg·kg-1 i.p.; Fig. 5b), indicating that it was mediated through the benzodiazepine-binding 
site of GABAA receptors. It was, however, insensitive to the opioid receptor antagonist 
naloxone (10mg·kg-1 i.p.), demonstrating that opioidergic pathways were not involved (Fig. 
5b). L-838,417 did not impair motor coordination (Fig. 5c). We next investigated the effects of 
L-838,417 against neuropathic pain and compared its analgesic efficacy and its liability to 
tolerance development (that is, its loss of analgesic activity) with that of morphine. L-838,417 
had a maximum analgesic effect comparable to that of morphine (20mg·kg-1 i.p.) (Fig. 5d), 
but unlike morphine it did not lose its efficacy during a chronic (nine-day) treatment period 
(Fig. 5 d, e).  
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Figure 5. Anti-hyperalgesic effects of the non-sedative benzodiazepine site ligand L-838,417 in 
rats.  
 
a, b, Inflammatory hyperalgesia induced by subcutaneous injection of zymosan A (1 mg) into one 
hindpaw. a, Effects of administration of L-838,417 (arrowed) on thermal hyperalgesia 6 h after 
injection of zymosan A (n = 4–6 rats). b, Effects of the benzodiazepine site antagonist flumazenil (F; 
10 mg·kg-1 i.p.) and the opioid receptor antagonist naloxone (N; 10 mg·kg-1 i.p.) on antinociception 
induced by administration of L-838,417 (L; 1 mg·kg-1 orally). N = 3 rats per group. c, Effects of L-
838,417 (1 mg·kg-1 orally) on motor control, shown as percentages of pre-drug rotarod performance (n 
= 8 rats per group). d, e, Neuropathic pain induced by CCI surgery. d, Anti-hyperalgesia by L-838,417 
and morphine after chronic treatment (once-daily i.p. injections) for 9 days with either drug (right) or 
vehicle (left), 16 days after CCI surgery. Dashed lines, thresholds before CCI surgery. e, Analgesic 
efficacy of L-838,417 ( L; 1 mg·kg-1) and morphine (M; 20 mg·kg-1) versus treatment duration. n = 6 
rats per group. For a comparison with the anti-hyperalgesic activity of intrathecal diazepam in rats see 
Fig. 6. All data are means ± s.e.m. 
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Figure 6. Antihyperalgesic effects of intrathecal diazepam (dzp) in the rat. 
 
Inflammatory hyperalgesia was induced by subcutaneous injection of 1 mg zymosan A into the left 
hindpaw. Dzp (0.09 mg/kg) was injected i.t. and paw withdrawal latencies (mean ± sem, n = 5 / group) 
were measured 6 hrs post Zymosan A injection. The maximum analgesia achieved in rats was similar 
to that obtained mice, but shorter lasting. 
 
 
Finally, functional magnetic resonance imaging (fMRI) was used to assess whether L-
838,417 would reduce not only nociceptive behaviour but also the representation of pain in 
the central nervous system. Changes in blood-oxygenation-level-dependent (BOLD) signals 
were quantified to measure brain activation evoked by noxious heat. Stimulation of the 
inflamed left or the non-inflamed right hindpaw led to reliable, often bilateral, activation of 
several brain regions involved in pain processing (Fig. 7). Significantly more brain volume 
was activated and stronger activation was seen on stimulation of the inflamed paw. L-
838,417 (1 mg·kg-1 i.p.) decreased brain activation induced by noxious heat after stimulation 
of the inflamed paw. For a quantitative assessment of its analgesic effects, we integrated the 
stimulus-correlated change in the BOLD signal (F) over all significantly activated voxels of 
each region of interest and calculated ΔF/F as (Fpost - Fpre)/Fpre, the relative decrease in F 
after injection of L-838,417 or vehicle (Table 2). Here we focused on brain areas that 
reflected either the sensory and discriminative component of pain (the medial thalamus and 
contralateral primary sensory cortex) or its emotional dimension (limbic system and frontal 
association cortex)23,24. After stimulation of the inflamed paw, a pronounced and statistically 
significant reduction in BOLD signal changes was observed in most brain regions analysed. 
Smaller changes in brain activation were found when the non-inflamed paw was stimulated 
and only negligible effects were seen after innocuous thermal stimulation (Table 2). These 
results indicate that systemically administered L-838,417 does indeed act as an anti-
hyperalgesic agent and reduces BOLD signals in brain areas related to both the sensory and 
the emotional associative components of pain.  
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Figure 7. Effects of L-838,417 (1 mg·kg-1 i.p.) on the supraspinal representation of pain.  
 
a, Anatomical slice indicating the position of the functional images. b, False-colour images of changes 
in BOLD signals evoked by stimulation of the left (inflamed) or right (non-inflamed) hindpaw with 
noxious heat. Images represent group maps across 12 rats averaged from 8 (pre-drug) and 16 (post-
drug) stimulations. Experiments started 6 h after subcutaneous zymosan A injection into the left 
hindpaw. MTh, medial thalamus; S1, primary somatosensory cortex; Cg, cingulate cortex; I, insular 
cortex; LS, limbic system (including amygdala, entorhinal cortex and hippocampus); HT, 
hypothalamus; HL, representation of hindlimb in S1. Left, left hemisphere. 
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Table 2. Changes in noxious heat-induced brain activation by L-838'417 measured by rat fMRI. 
 
 Stimulation of inflamed paw with 
noxious heat 
 Stimulation of non-inflamed paw 
with noxious heat 
 Stimulation of non-inflamed paw with 
innocuous temperature 
area ΔF/F 
(mean±sem) 
Incidence* sign. vs. 
predrug 
(P)+ 
 ΔF/F 
(mean±sem)
Incidence* sign. vs. 
predrug 
(P)+ 
 ΔF/F 
(mean±sem) 
Incidence* sign. vs. 
predrug 
(P)+ 
MTh -0.35 ± 0.07 10/12 0.014  -0.29 ± 0.09 10/12 0.069  -0.10 ± 0.07 6/12 0.302 
S1c -0.29 ± 0.07 12/12 0.028  -0.07 ± 0.09 12/12 0.383  -0.18 ± 0.25 11/12 0.228 
Cg -0.37 ± 0.07 11/12 0.034  -0.26 ± 0.08 12/12 0.078  -0.07 ± 0.08 10/12 0.152 
FAC -0.55 ± 0.05 12/12 0.007  -0.30 ± 0.08 12/12 0.179  -0.09 ± 0.08 6/12 0.253 
LS -0.36 ± 0.05 11/12 0.012  -0.06 ± 0.07 12/12 0.580  -0.04 ± 0.07 11/12 0.413 
MTh, medial thalamus; S1c, primary somatosensory cortex contralateral; Cg, cingulate cortex; FAC, frontal association cortex; LS, limbic system (including 
amygdala, entorhinal cortex and hippocampus). 
* number of rats, in which a significant noxious heat-induced activation of the respective area occurred / total number of rats studied 
+ paired Student t-test 
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Considerable evidence indicates that a facilitation of GABAergic inhibition can be pro-
nociceptive at supraspinal sites, for example the rostral agranular insular cortex25 or in the 
periaqueductal grey26, by reducing the activity of descending antinociceptive neurons. At 
these sites most GABAA receptors apparently contain the α1 subunit27. Therefore, not only 
would sparing the α1 subunit avoid unwanted sedation, it would also increase analgesic 
efficacy. Aside from sedation and tolerance development, addictive properties are of major 
concern in the development of analgesics. Available evidence indicates that subtype-
selective benzodiazepine-site ligands should exhibit at most only modest addictive 
properties28 and should not lead to tolerance development29. Finally, previous studies have 
shown that in neuropathic pain after injury to peripheral nerves, GABAergic inhibition can not 
only be diminished but it can even turn into excitation6,7. Our results suggest that sufficient 
inhibition remains to permit a spinal analgesic effect of drugs that increase GABAergic 
neurotransmission. Because glycine and GABA are released together at many inhibitory 
synapses in the dorsal horn30, a facilitation of GABAergic transmission should also be able to 
compensate for a selective decrease in glycinergic inhibition3. Thus, we have not only 
identified the GABAA receptors containing the α2 and α3 subunits as critical components of 
spinal pain control, but also demonstrated that α1-sparing benzodiazepine-site ligands, 
which are already in development as anxioselective (non-sedative) agents, might constitute a 
class of analgesics suitable for the treatment of chronic pain syndromes. 
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Abstract 
γ-amino butyric acid (GABA) is a major inhibitory neurotransmitter in spinal dorsal horn, a key 
site of nociceptive processing. Here, ionotropic GABA (GABAA) receptors are expressed not 
only at classic postsynaptic sites, but also at the spinal terminals of primary afferent 
nociceptors where they contribute to presynaptic inhibition. Many of these presynaptic 
GABAA receptors belong to the α2 subunit containing type (α2-GABAA receptors), which is 
also largely responsible for the antihyperalgesic action of spinal benzodiazepines. The 
contribution of presynaptic α2-GABAA receptors to the spinal control of nociception and to 
the antihyperalgesic effect of spinal diazepam (dzp) is not known. Here, we address these 
questions through the use of conditional nociceptor-specific α2-GABAA receptor deficient 
(sns-α2-/-) mice, and with conditional (sns-α2R/-) point-mutated mice, whose primary 
nociceptor α2-GABAA receptor subunits have been rendered dzp-insensitive. We found that 
the amplitudes of GABAA receptor currents recorded from nociceptive dorsal root ganglion 
(DRG) neurons were unchanged in sns-α2-/- mice but their potentiation by dzp was 
significantly reduced. Accordingly, presynaptic inhibition of primary afferent evoked synaptic 
transmission in the superficial dorsal horn induced by the GABAA receptor agonist muscimol 
was unchanged in sns-α2-/- mice, but additional application of dzp-induced failures in 
synaptic transmission in wild-type mice only. In line with these in vitro results, behavioral 
experiments revealed unchanged nociceptive thresholds and unchanged inflammatory and 
neuropathic hyperalgesia in sns-α2-/- mice, but a decreased effect of spinal dzp against 
inflammatory hyperalgesia in sns-α2-/- (and sns-α2R/-) mice. Our experiments did not reveal a 
contribution of presynaptic α2-GABAA receptors to endogenous pain control in mice but 
demonstrate a significant contribution of these receptors to dzp-induced anti-hyperalgesia in 
inflammatory pain states. 
 
Introduction  
GABAA receptors mediate fast synaptic inhibition throughout most parts of the adult 
mammalian central nervous system. They are also densely expressed in the spinal dorsal 
horn (1) where they control the propagation of nociceptive signals from the periphery to 
higher CNS areas (2, 3). Many lines of evidence indicate that diminished inhibitory 
GABAergic and glycinergic control at this site is a major factor in chronic pain syndromes ((4-
8), for a review see (9)). Conversely, hyperalgesia originating from inflammatory and 
neuropathic disease states can be reversed by local spinal and systemic administration of 
the GABAA receptor agonist muscimol (10) or of benzodiazepines such as dzp (11, 12) and 
midazolam (13), which facilitate the action of GABA at GABAA receptors. These GABAA 
receptors are heteropentameric ligand-gated ion channels, composed of α, β and γ subunits 
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in a 2:2:1 stoichiometry (14, 15). All benzodiazepine-sensitive GABAA receptors contain one 
γ2 subunit, which together with an α1, α2, α3, or α5 subunit forms the benzodiazepine 
binding-site (16). GABAA receptor point-mutated mice have been generated in which each of 
the GABAA receptor α subunits has individually been rendered dzp-insensitive (17-19) with 
no change in the responses to the endogenous activator GABA. With these mice, it has 
become possible to attribute to α2-GABAA receptors not only the anxiolytic action of dzp (19), 
but also most of its spinal antihyperalgesic effect (11, 12).  
These α2-GABAA receptors are not only found postsynaptically on central dorsal horn 
neurons, where they cause classic postsynaptic inhibition through hyperpolarization and 
activation of a shunting conductances, but a wealth of evidence indicates that they are also 
expressed presynaptically, on the spinal terminals of primary afferent nociceptive fibers (1). 
Due to a very peculiar expression pattern of chloride transporters (20, 21) and a resulting 
unusually high intracellular chloride concentration, GABAA receptor activation depolarizes 
rather than hyperpolarizes these terminals (22, 23) and give rise to a phenomenon known as 
primary afferent depolarization (PAD) (24, 25). This depolarization is nevertheless believed 
to cause presynaptic inhibition, i.e. reduce synaptic glutamate release from the spinal 
primary afferent terminals, most likely through voltage-dependent inactivation of presynaptic 
Na+ or Ca2+ channels or through activation of a shunting conductance along the axon (26). 
However, if PAD becomes sufficiently strong to trigger action potentials, it may also cause so 
called dorsal root reflexes and exaggerate pain and inflammation (27, 28). 
Although dorsal root potentials arising from the activation of presynaptic GABAA receptors in 
the spinal cord have been studied for decades, their functional contribution to the processing 
of nociceptive signals and to the antihyperalgesic effect of spinally applied benzodiazepines 
is still unknown, mainly due to lack of suitable tools for the specific targeting of presynaptic 
GABAA receptors. Here, we have used a genetic approach to address these questions and 
investigated conditional nociceptor-specific α2-GABAA receptor-deficient and point-mutated 
mice in morphological, electrophysiological and behavioral experiments. Nociceptor-specific 
α2-GABAA receptor deletion left GABAergic membrane currents in nociceptive DRG neurons 
and GABAA receptor-mediated presynaptic inhibition largely unchanged, but reduced their 
sensitivity to dzp and led to a reduction in the antihyperalgesic effect of spinally injected dzp. 
 
Materials and Methods 
Mice. To generate a floxed gabra2 allele, a 6.3 kb PstI-NcoI genomic fragment was isolated, 
which contains 2 SphI sites. The 1 kb SphI-SphI fragment was removed from the 6.3 kb PstI-
NcoI fragment and replaced by an oligo hybrid containing a loxP site with adjacent KpnI and 
SalI sites, recreating a single SphI site, into which the 1 kb SphI-SphI fragment containing 
exon 5 (221 bp) was reinserted. A neomycine resistance cassette (FRT-Pol2-neo-bpA-FRT-
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loxP) was then subcloned into the SalI site mentioned above. The genomic homology also 
contains exon 6 (83 bp). 3’ adjacent to the genomic homology, a HSV-TK cassette was 
inserted. The vector backbone was pBC. The vector was linearized at the 5’ end of the 
genomic homology at a NotI site. ES cells (C57BL/6N, Eurogentec) were electroporated and 
clones harboring a single targeting event (targeted allele) were obtained and injected into 
blastocysts (Polygene, Ruemlang, Switzerland), and germline transmission was obtained. 
The neomycine resistance cassette was bred out using ACTFlpe mice (Jackson 
Laboratories, Bar Harbor, Maine, stock number 005703) to obtain the floxed allele 
(Gabra2tm2.1Uru.). Floxed mice were crossed with EIIa-cre mice (Jackson Laboratory, Bar 
Harbor, Maine, stock number 003724) to obtain gabra2 global knockout mice.  The 
designation of the knockout allele is: gabra2tm2.2Uru. 
Nociceptor-specific GABAA receptor α2-deficient or nociceptor-specific GABAA receptor α2 
point-mutated mice were generated from sns-cre transgenic mice (29) crossed with α2fl/fl or 
α2fl/fl and α2R/R (19) mice (for details of the breeding schemes see Fig. 1). All mice were 
maintained on a C57BL/6 background. To exclude possible confounding factors arising from 
the sns-cre transgene itself (41), we analyzed mice which carried the sns-cre transgene but 
no mutations in the gabra2 gene. These mice developed normal inflammatory hyperalgesia 
and responded normally to intrathecal dzp (Fig. 6). 
 
Mouse genotyping by polymerase chain reaction. The following polymerase chain 
reaction primers were used to identify the cre transgene (5’-TGA CAG CAA TGC TGT TTC 
ACT GG-3’ and 5’-GCA TGA TCT CCG GTA TTG AAA CTC C-3’, providing a product size of 
607 bp), the GABAA α2 point-mutated α2(H101R; R) allele (5’- TCC ATC ATC CTG GAT 
TCG AAG CAG C-3’ and 5’-GCA TGC ACC ACC CAG GAA GCG ATT-3’, providing a 
product size of 526 bp for the wildtype (H) or floxed (Hflox) allele and 561 bp for the point-
mutated (R) allele), and the floxed GABAA α2 allele (5’- TAT CTT GTC TTT CCC CTC CTG 
GTT G-3’ and 5’- CAG GAT AGG GAA GCA GGA GTG G-3’, providing a product size of 289 
bp for the wildtype (H) or point-mutated (R) allele and around 330 bp for the floxed α2 allele. 
The regions amplified for the floxed allele and for the α2(H101R) allele are separated. 
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Figure 1. Breeding schemes and description of the genotypes of mice used in the present 
study.  
 
A, breeding scheme to obtain nociceptor-specific α2-/- (HfloxHflox/sns-cretg+) mice and their pseudo-wild-
type litter mates (α2fl/fl). B, breeding scheme to obtain nociceptor-specific α2R/- (HfloxR/sns-cretg+), α2-/H 
(HfloxH/sns-cretg-), and corresponding control mice (global heterozygous and pseudo-wild type).  C, 
genotypes of all mouse lines. Hflox, α2 floxed allele; H, α2 wild-type allele with a codon for histidine at 
amino acid position 101; R, α2(H101R) point-mutated allele with a codon for arginine at amino acid 
position 101; sns-cretg, absence (-) or presence (+) of cre transgene. 
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Gene expression analysis by real-time PCR. Lumbar dorsal root ganglia (4 per tube), 
lumbar spinal cords and cerebral cortices from adult (7-10 weeks) sns-α2-/- mice and α2fl/fl 
littermates, and from global α2-/- mice, were rapidly removed following decapitation of the 
mice in ice-cold carbogen-saturated extracellular solution (see more below). Biopsies were 
collected in a tube containing a lysis solution and total RNA was isolated by using 
GenEluteTM Mammalian Total RNA Miniprep Kit (RTN70, Sigma-Aldrich). gDNA was 
removed and cDNA was generated in a reaction mixture using QuantiTect®  Reverse 
Transcription Kit (Cat.No. 205311, Qiagen®). Real-time quantitative PCR (qPCR) was 
performed analyzed using TaqMan® Gene Expression Master Mix (Part No. 4369016, 
Applied Biosystems) with generated cDNA in a total reaction volume of 10 μl in 384-Well 
arrays with 7900HT Fast Real-Time PCR System and software (Applied Biosystems). mRNA 
expression of the benzodiazepine-sensitive GABAA receptor α subunits (α1, α2, α3, α5) was 
quantified using pre-designed coding assays (FAM™ dye-labeled TaqMan® MGB probes; 
Applied Biosystems) (Table 1). The Real-time qPCR cycling program consisted of 95 °C for 
10 min, followed by 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. The expression level 
of each targeted gene was normalized to that of the β-actin gene, which was used as a 
reference. All qPCR reactions were carried out in triplicate. Relative quantification of 
transcript was determined using the comparative CT method (2−ΔCT) calibrated to β-actin.
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Table 1. Assay probes used in the qRT-PCR analysis. 
 
 
Assay ID 
 
 
Context 
Sequence 
 
 
Gene 
 
 
Gene Name 
 
 
Species 
 
 
Exon 
Boundary 
 
 
Mm00607939_s1* 
 
 
 
CTGTTACTG
AGCTGCGT
TTTACACC 
 
 
Actb 
 
 
actin, beta, 
cytoplasmic 
(reference gene) 
 
 
Mus musc. 
 
 
6 
 
 
Mm00439046_m1*
* 
 
TTCCAGAAA
AGCCAAAG
AAAGTAAA 
 
 
Gabra1 
 
 
GABAA receptor, 
subunit alpha 1 
 
 
Mus musc. 
 
 
9-10 
 
 
 
Mm00433435_m1*
* 
 
 
TATATACCA
TGAGGCTT
ACAGTCCA 
 
 
Gabra2 
 
 
GABAA receptor,  
subunit alpha 2 
 
 
Mus  musc. 
 
 
5-6 
 
 
Mm00433440_m1*
* 
 
 
AGTGACTG
TGACACTC
GATCTCAC
A 
 
 
Gabra3 
 
 
GABAA receptor, 
subunit alpha 3 
 
 
Mus musc. 
 
 
1-2 
 
 
Mm00621092_m1*
* 
 
 
ACACCATG
CGTCTGAC
AATCTCTGC
 
 
Gabra5 
 
 
GABAA receptor, 
subunit alpha 5 
 
 
Mus musc. 
 
 
5-6 
 
 
*) The assay’s primers and probes are designed within a single exon and will detect genomic 
DNA. 
 
**) The assay’s probe spans an exon junction and will not detect genomic DNA. 
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Preparation of spinal cord slices for electrophyiological experiments. 2 - 3 week-old 
mice were anesthetized with isoflurane and subsequently sacrificed by decapitation. The 
spinal cord was removed after laminectomy in ice-cold extracellular solution, fixed on 
gelatine block and were sliced into transverse sections (300-350 μm) with few dorsal roots. 
Slices were kept in extracellular solution 120 mM NaCl, 5 mM Na-HEPES, 26 mM NaHCO3, 
1.25 mM NaH2PO4, 2.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM glucose (pH 7.35, 300 
mOsm) at physiological temperature around 35°C and bubbled with 95% O2 / 5% CO2. 
 
Electrophysiology. DRG neurons were prepared from 3 - 4 week old sns-α2-/- and α2fl/fl 
mice as described previously (11). GABAergic membrane currents and their potentiation by 
dzp were studied in nociceptive DRG neurons identified through the presence of Na+ current 
remaining in the presence of TTX (0.3 µM) (31, 42, 43). Spinal cord slices were prepared 
from 2 - 3 week-old mice (7). Primary afferent EPSCs were elicited at a frequency of 0.07 Hz 
through electrical stimulation of short dorsal rootlets attached to the spinal cord slices, and 
recorded from LI/II neurons. Cl- was replaced by F- in the intracellular solution to avoid the 
activation of GABAA receptor-meditated membrane currents in the recorded neuron during 
perfusion with muscimol. All recordings were made at room temperature. 
 
Behavior. Experiments were done in 7-10-week old mice of both sexes. Inflammatory and 
neuropathic pain induction, as well as thermal and mechanical testing was done as 
described previously (11). Acute C fiber-mediated nociception was tested following 
subcutaneous capsaicin (1.6 μg / 10 μl vehicle [10% Tween 80, 10 % ethanol, 80 % saline]) 
injection and flexor responses (flinches) were counted for 5 min following injection. C-fiber-
dependent secondary hyperalgesia was induced through capsaicin (30 µg / 10 µl vehicle 
[10% Tween 80, 10 % ethanol, 80 % saline] injection into the plantar side of the left hind paw 
(44). Permission for the animal experiments was obtained from the Veterinäramt des 
Kantons Zürich (ref. no. 121/2006 and 34/2007). 
 
Morphology. Lumbar spinal cords prepared from 6 - 8 week old sns-α2-/- mice and α2fl/fl 
littermates were cut into 300 µm thick parasagittal slices, fixed in 4% paraformaldehyde for 
10 min and subsequently cut into 14 µm thick sections using a cryostat. Immunofluorescence 
stainings were made to study the co-localization of GABAA receptor α2 and α3 subunits 
(guinea pig affinity purified antisera; (11)) with markers of primary afferent fibers. Polyclonal 
rabbit antisera against CGRP (Chemicon, California, USA, cat. no. AB 15360) and an 
isolectin B4 (IB4)-Alexa 488 conjugate (Molecular Probes, Eugene, OR, USA, cat. no. 
121411) were used to label the spinal terminals of peptidergic and non-peptidergic C fibers, 
respectively. Myelinated fibers were retrogradely labeled with cholera toxin B subunit (CTB, 
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Sigma-Aldrich, St. Louis, MO, USA, 2 µg) injected slowly (within 10 min) in a volume of 2 µl 
into the left sciatic nerve proximal to its trifurcation. 7 days after injection, mice were 
sacrificed. CTB was detected with goat anti-CTB serum (List Biological Laboratories, 
Campbell, CA, cat. no. 703). High-resolution confocal images were processed and analyzed 
with Imaris (Bitplane). 
 
Results 
Conditional nociceptor-specific  α2-GABAA receptor-deficient mice (gabra2 HfloxHflox/sns-
cretg+; short sns-α2-/- mice) were generated by crossing mice carrying a floxed α2-GABAA 
receptor (gabra2) gene (Fig. 1 and 2A; for details see Materials and Methods) to bacterial 
artificial chromosome transgenic mice expressing the cre combinase under the 
transcriptional control of the sensory neuron specific sodium channel (sns) gene (29). To 
quantify changes in GABAA receptor α2 subunit expression and to test for possible 
compensatory up- or down-regulation of other benzodiazepine-sensitive GABAA receptor α 
subunits, we first employed qRT-PCR (detecting the floxed gabra2 gene segment) in lumbar 
DRGs and spinal cords, and cerebral cortices (Fig. 2B,C). Compared to α2fl/fl mice, sns-α2-/- 
mice showed a 66.2 ± 1.3% (n = 7) reduction in GABAA receptor α2 subunit mRNA 
expression with no significant changes in spinal cord and cerebral cortex (Fig. 2B). The 
expression of the other benzodiazepine-sensitive GABAA receptor α subunits was not 
significantly changed in DRGs of sns-α2-/- mice (Fig. 2C). No detectable levels of α2 
subunit mRNA were found in global α2-/- mice (which were generated from the same α2fl/fl 
mice through EIIa-cre mice (30) suggesting that the α2 mRNA levels remaining in the sns-
α2-/- mice derived most likely from non-nociceptive (sns-cre-negative) DRG neurons.  
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Figure 2. Generation of GABAA receptor α2fl/fl mice and qRT-PCR analyses. 
 
(A) Generation of mice carrying a floxed gabra2 allele . Removal of the Neo cassette, flanked by 
flippase recognition targets (frt) by the flippase (Flp) and the removal of the flanked region by loxP 
sites by the Cre recombinase, respectively. The two bars show exon 5 (x5) and 6 (x6). (B) 
Quantification (mean ± sem) of gabra2 transcript numbers (relative to β-actin) in lumbar DRGs, spinal 
cords and cerebral cortices of sns-α2-/- mice (n = 7) and wild type (α2fl/fl) littermates (n = 9) with qRT-
PCR. (C) Quantitative analysis of changes in the copy number of gabra1, gabra2, gabra3 and gabra5 
gene transcripts (encoding for the benzodiazepine-sensitive subunits α1, α2, α3, and α5) in the DRGs 
of sns-α2-/- mice and wild type (α2fl/fl) littermates. ***, P ≤ 0.001 Statistical comparisons between wild-
type and sns-α2-/- mice were made with Student t tests followed by Bonferroni correction for three (B) 
and four (C) independent comparisons. 
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High resolution confocal microscopy was used in coronal section of the lumber spinal cord to 
study the co-localization of α2-GABAA receptors with calcitonin gene related peptide (CGRP) 
and isolectin B4 (IB4), two markers of peptidergic and non-peptidergic C fiber nociceptors, 
respectively (Fig. 3A). In dorsal horn layers I and II of α2fl/fl mice, about one third and one 
fourth of the CGRP and IB4 positive axon terminals also stained positive for α2-GABAA 
receptors. These co-localizations were dramatically reduced in sns-α2-/- mice (Fig. 3B). To 
study co-localizations in non-nociceptive (myelinated) axons, we labeled these fibers 
retrogradely through injection of cholera toxin B subunit (CTB) into the sciatic nerve of 
anesthetized mice. CTB-positive structures were mainly located in the deep dorsal horn and 
showed only very little co-localization with α2-GABAA receptors. Interestingly, much of the 
total α2 immunoreactivity was retained in sns-α2-/- mice, which together with the low 
expression of α2 in myelinated primary afferents, indicates that a major portion of dorsal horn 
α2-GABAA receptors reside on central neurons rather than on primary afferent terminals. 
Rather unexpectedly, we found similar degrees of co-localization with CGRP- and IB4-
positve terminals also for α3-GABAA receptors (Table 2).  
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Figure 3. α2-GABAA receptors in the spinal dorsal horn.  
 
(A) Double immunofluorescence stainings showing co-localization of α2-GABAA receptors (red) with 
peptidergic (CGRP-positive, lamina II outer) and non-peptidergic (IB4-positive, lamina II inner) axons 
and terminals (green) in parasagittal sections of lumbar spinal cords of adult wild type (α2fl/fl) and sns-
α2-/- mice. Scale bar, 5 µm. (B,C) Higher magnification of the areas indicated in (A). Scale bars, 0.5 
µm. (B) α2-GABAA receptor immunoreactivity. (C) Co-localization. Arrows indicate co-localizations. (D) 
Statistical analysis. Per cent co-localization (mean ± sd) of CGRP, IB4 and CTB-positive axons and 
terminals with α2-GABAA receptors. Co-localizations were counted in 6 fields per slide. Each slide was 
from different mouse and 3 mice per genotype were analyzed. ANOVA followed by Bonferroni post 
hoc test F(5,12) = 47.0; ***, P ≤ 0.001. Co-localization of CTB with α2-GABAA receptors was assessed 
in lamina III of the dorsal horn.  
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Table 2. Percentage colocalization of α3 clusters with the primary afferent terminals. 
 
 
 
 
 
 
 
To analyze functional consequences of sns-α2 gene deletion for GABAergic membrane 
currents, we made whole-cell recordings from acutely isolated nociceptive DRG neurons 
identified by the presence of Na+ currents remaining in the presence of tetrodotoxin (TTX, 0.3 
µM) (31). No significant changes in the amplitude of GABAergic membrane currents were 
found between DRG neurons isolated from sns-α2-/- mice and α2fl/fl littermates, but the 
facilitation of GABAergic currents by dzp (1 μM) was significantly reduced in the sns-α2-/- 
group (Fig. 4A). We next analyzed the modulation of primary afferent-evoked synaptic 
transmission through presynaptic GABAA receptors. In sns-α2-/- mice, α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated excitatory postsynaptic currents 
(EPSC) were recorded from superficial (lamina I/II) dorsal horn neurons upon electrical 
stimulation of short dorsal roots. 
To avoid the activation of GABAA receptors in the recorded neurons, intracellular Cl- was 
replaced by F- (32), which does not permeate GABAA gated Cl- channels (33).  Amplitudes of 
AMPA-EPSCs were not significantly different between neurons recorded from sns-α2-/- and 
α2fl/fl littermates and similarly decreased by muscimol (0.1 µM and 5 µM) (figure 4B). We next 
studied the effect of dzp on the inhibitory action of a low concentration of muscimol (0.1 μM). 
Muscimol alone had only a minor effect on AMPA-EPSCs, but when dzp (1 μM) was applied 
in addition to muscimol, the rate of “successful” stimulation decreased significantly (Fig. 4C) 
consistent with a presynaptic site of action.  
 
 
 CGRP IB4 CTB 
 % SD SEM % SD SEM % SD SEM 
α2 fl/fl 52.2 11.88 6.86 40.6 15.82 9.14 3.0 5.37 3.10 
sns-α2-/- 43.5 9.01 5.20 41.0 33.41 19.29 0.5 0.87 0.50 
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Figure 4. GABAergic membrane currents and primary afferent synaptic transmission in sns-α2-
/- mice. 
 
(A) GABAergic membrane currents recorded from acutely isolated nociceptive DRG neurons. Left: 
individual current traces evoked through puffer application of GABA (1 mM) to the soma of DRG 
neurons of α2fl/fl (n = 26) and sns-α2-/- mice (n = 14) and recorded in the absence (black) and 
presence (red) of dzp (1 µM). Right: statistical analyses (mean ± sem). Absolute amplitudes and 
percent potentiation by dzp. *, P < 0.05 (unpaired t test). (B, C) Primary afferent evoked EPSCs 
recorded from lamina I/II neurons in coronal spinal cord slices of α2fl/fl and sns-α2-/- mice. (B) left: 
current traces under control conditions (black) and in the presence of muscimol (5 µM, red). Right: 
statistical analyses (mean ± sem). EPSC amplitudes: unpaired t test, n = 19 (α2fl/fl), n = 18 (sns-α2-/-); 
inhibition by muscimol: n = 6 - 17. (C) Analyses of synaptic failure rates. Left: superposition of 10 
consecutive primary afferent-evoked EPSCs under control conditions, in the presence of muscimol 
(0.1 µM) and in the additional presence of dzp (1 µM). Right: statistical analysis (mean ± sem). n = 17 
(α2fl/fl), n = 10 (sns-α2-/-). ANOVA (genotype * treatment); F (3,81) = 3.96; P = 0.03; **, P < 0.01 
significant against α2fl/fl; +++, P < 0.01 significant against control.  
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We next analyzed possible phenotypes of sns-α2-/- mice in tests of acute nociception and in 
models of inflammatory and neuropathic hyperalgesia. sns-α2-/- mice responded normally to 
exposure of one hindpaw to noxious heat or to mechanical stimulation with von Frey 
filaments. They also exhibited normal nociceptive (flexor) responses (flinches) after chemical 
activation of nociceptors with subcutaneously injected capsaicin (Fig. 5A). Next, we analyzed 
the mice in inflammatory and neuropathic pain models. sns-α2-/- and α2fl/fl mice developed 
virtually identical thermal and mechanical hyperalgesia (Fig. 5B,C) and indistinguishable 
inflammatory paw swelling (Fig. 5D) after subcutaneous injection of the yeast extract 
zymosan A. Likewise, sns-α2-/- and α2fl/fl mice responded with nearly identical thermal and 
mechanical hyperalgesia after chronic constriction of the sciatic nerve (Fig. 5E,F), and 
developed normal mechanical hyperalgesia after subcutaneous capsaicin injection (Fig. 5G).  
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Figure 5. Nociceptive behavior in sns-α2-/- mice. 
 
(A) Baseline nociceptive sensitivity. Paw withdrawal latencies (s) in response to stimulation with a 
defined radiant heat stimulus (left), mechanical thresholds (g) to stimulation with dynamic von Frey 
filaments (middle), and numbers capsaicin-induced flinches (right) in sns-α2-/- mice and in wild type 
(α2fl/fl) littermates. Mean ± sem, n = 6-10 mice / group, P > 0.05 (unpaired t test). (B-D) Inflammation 
induced by subcutaneous zymosan A injection (0.06 mg/ 10 μl) into the plantar side of the left hind 
paw. Thermal hyperalgesia (paw withdrawal latencies, s) (B), mechanical sensitization (withdrawal 
thresholds, g) (C), and paw swelling (D) in sns-α2-/- and wild type (α2fl/fl) mice. Left: time course, right: 
statistics, area under the curve (AUC, mean ± sem). n = 6 - 10 mice / group, P > 0.05 (unpaired t test). 
(E, F) Same as B, C, but neuropathic pain induced through chronic constriction injury of the left sciatic 
nerve. n = 6 mice / group. (G) Secondary hyperalgesia induced through subcutaneous injection of 
capsaicin (30 μg / 10 μl) into the plantar left hind paw. Mechanical withdrawal thresholds (g). Left: time 
course, right: statistics, area under the curve (AUC, mean ± sem). Mean ± sem, n = 5 - 6 mice/group. 
P > 0.05 (unpaired t test).  
(A-G) open symbols, wild type (α2fl/fl); filled symbols, sns-α2-/-; (B-G) circles, ipsilateral paws; squares, 
contralateral paws. 
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Figure 6. Antihyperalgesic effects of dzp in sns-cretg- and sns-cretg+ mice in the Zymosan A 
inflammatory model. 
 
Antihyperalgesic effects of intrathecal dzp (0.09 mg / kg body weight) on thermal (top), and 
mechanical (bottom) hyperalgesia expressed as paw withdrawal latency (s) or paw withdrawal 
threshold (g), respectively. AUC, area under the curve (0 - 4 h after dzp injection).  
Inflammatory hyperalgesia induced by subcutaneous zymosan A injection (0.06 mg / 10 μl) into the left 
hind paw. Dzp was given 48 hours after zymosan A injection. 
Mean ± sem, n = 7-9 mice/group. P > 0.05 (unpaired t-test). Open black symbols, (sns-cretg-); filled red 
symbols, sns-cretg+; circles, ipsilateral paws; squares, contralateral paws. 
 
 
In a separate set of experiments we assessed the consequences of the sns-α2 gene deletion 
for the antihyperalgesic effect of spinally applied dzp in the three pathological pain models. 
The effect of dzp (0.09 mg/kg body weight, compare (11)) injected intrathecally at the level of 
the lower lumbar spine was tested when hyperalgesia had reached a maximum, i.e. after 2 
and 7 days in the zymosan A and CCI model, respectively, and after 2 hours in the capsaicin 
model of central hyperalgesia. Dzp reversibly reduced inflammatory thermal hyperalgesia 
and mechanical sensitization in α2fl/fl mice. This antihyperalgesia was significantly reduced in 
both sns-α2-/- and global α2-GABAA point mutated mice (α2R/R mice) (Fig. 7A,B). In the 
experiments addressing mechanical hyperalgesia we included in addition to sns-α2-/- and 
α2R/R mice also nociceptor-specific α2-GABAA receptor point-mutated mice (sns-α2R/-), which 
carry dzp-insensitive α2-GABAA receptors specifically in primary nociceptors and a global 
heterozygous point mutation which is not dzp-insensitive in other cells (see figure 1). These 
mice exhibited a reduction in dzp-induced antihyperalgesia, which was similar that observed 
in sns-α2-/- rendering compensatory up-regulations of other dzp-sensitive GABAA receptors in 
the sns-α2R/- unlikely. Importantly, sns-α2+/- (hemizygous nociceptor-specific knock-out) 
mice, and α2R/fl (heterozygous point mutated) mice did not differ significantly from α2fl/fl mice 
(data not shown).  
Although intrathecal dzp was similarly effective in inflammatory and neuropathic pain states 
and although both effects were mainly mediated by α2-GABAA, neither sns-α2-/- nor sns-α2R/- 
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mice exhibited reduced dzp-induced antihyperalgesia in the CCI model of neuropathic pain 
(Fig. 7C,D) and in capsaicin-induced central hyperalgesia (Fig. 7E).  
 
 
Figure 7. Anti-hyperalgesic effects of dzp in sns-α2-/- and sns-α2R/- mice. 
 
Anti-hyperalgesic effects of intrathecal dzp (0.09 mg / kg body weight) on thermal (A,C), and 
mechanical (B,D,E) hyperalgesia expressed as per cent maximum possible analgesia (mean ± sem). 
AUC, area under the curve (0 - 4 h after dzp injection). (A, B) Inflammatory hyperalgesia induced by 
subcutaneous zymosan A injection (0.06 mg / 10 μl) into the left hind paw. Dzp was given 48 hours 
after zymosan A injection Left: time course; Right: statistics. AUC expressed as per cent of wild type 
littermates (α2fl/fl mice). ANOVA F (2,25) = 8.71 followed by Bonferroni post hoc test, n = 8 - 10 mice / 
group (thermal hyperalgesia); ANOVA F (3,33) = 36.82, n = 7 - 12 mice/group (mechanical 
hyperalgesia). (C, D) Same as (A, B) but neuropathic pain induced by chronic constriction injury of the 
left sciatic nerve. Anti-hyperalgesic effects were assessed 7 days after surgery. Statistics: ANOVA 
followed by Bonferroni post hoc test F (2,21) = 5.18, n = 7 - 9 mice / group (thermal hyperalgesia); F 
(3,23) = 11.16, n = 5 - 10 mice/group (mechanical hyperalgesia). (E) Same as B, but secondary 
hyperalgesia induced through subcutaneous injection of capsaicin (30 μg / 10 μl) into the plantar left 
hind paw. Dzp was injected 2 hours after capsaicin. AUC, 0 – 3 h after dzp injection. Statistics: 
ANOVA followed by Bonferroni post hoc test F (3,31) = 17.15, n = 6 - 12 mice / group. *, **, *** P ≤ 
0.05, P ≤ 0.01, P ≤ 0.001, significant against α2fl/fl, +, +++; P ≤ 0.05, P ≤ 0.001, against α2R/R. 
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Discussion 
We have used here a genetic approach to investigate the contribution of presynaptic GABAA 
receptors on the spinal nociceptor terminals to pain control under physiological conditions 
and in different pain pathologies. Previous in-situ hybridization (34, 35), immunofluorescence 
(1, 11), and electrophysiological (11) experiments have suggested that presynaptic GABAA 
receptors on dorsal horn nociceptor terminals are mainly, if not exclusively, of the α2 
subtype. Our confocal double labeling experiments indeed show that a large portion 
(between one third and one forth) of the peptidergic and non-peptidergic fibers express α2-
GABAA receptors, but they also carry comparable amounts of α3 subunits. This is consistent 
with the results of our electrophysiological experiments, which demonstrated the presence of 
GABAergic membrane currents of similar amplitude in nociceptive DRG neurons from sns-
α2-/- mice. The diminished dzp-sensitivity of these currents may suggest an additional 
compensation by dzp-insensitive GABA receptors formed e.g. by ρ subunits which have 
previously been reported in nociceptive DRG neurons (36).  
The most obvious phenotype observed in the sns-α2-/- mice was a reduction in the 
antihyperalgesic effect of intrathecal dzp against inflammatory hyperalgesia showing that a 
significant part of this antihyperalgesic effect originated from increased presynaptic 
GABAergic inhibition. The total contribution of the α2 subunit to spinal dzp-mediated 
antihyperalgesia was about 70%. Of these 70%, about two thirds were lost both in 
nociceptor-specific knock-out (sns-α2-/-) and knock-in (sns-α2R/-) mice. This presynaptic 
component was similar for both thermal and mechanical hyperalgesia indicating that the 
responses to both types of stimuli were triggered by nociceptors, and that large myelinated 
fibers were less important. The reduced antihyperalgesia in sns-α2-/- mice correlates well 
with our electrophysiological data which indicated a reduced dzp-sensitivity of GABAergic 
membrane currents in primary nociceptors and a diminished ability of dzp to increase the 
failure rate of primary afferent evoked EPSCs recorded from superficial dorsal horn neurons. 
The α2-GABAA receptor-mediated antihyperalgesia remaining in sns-α2-/- mice most likely 
originates from postsynaptic α2-GABAA receptors, whose existence in the dorsal horn has 
not been generally accepted previously, because in situ hybridization studies had revealed 
significant amounts of α2 mRNA only in the ventral and not in the dorsal horn (34). However, 
the present immunofluorescence experiments, in which most of the α2 fluorescence in the 
superficial layers was retained in sns-α2-/- mice, and our previous electrophysiological 
experiments, which had shown a reduction in dzp-sensitivity of dorsal horn neurons of α2R/R 
mice (11), strongly support a significant postsynaptic localization also in the dorsal horn.  
In striking contrast with the antihyperalgesic activity of spinal dzp against inflammatory pain, 
its activity against neuropathic pain induced by sciatic nerve constriction was not changed in 
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sns-α2-/- nor sns-α2R/- mice. This is particularly surprising because the total contribution of 
α2-GABAA receptors to dzp-induced spinal antihyperalgesia was very similar in both pain 
models. Two findings from other groups may offer an explanation. Early studies on dorsal 
root potentials in rats demonstrated reduced GABA sensitivity of spinal primary afferent 
nerve terminals after peripheral nerve injury (37). More recently, gene expression studies in 
DRGs revealed a reduced expression of the GABAA receptor γ2 subunit (38) which is 
required for dzp-induced potentiation of GABAA receptor activation (but see also (39)).  
The fact that nerve injured sns-α2-/- or sns-α2R/- mice responded normally to intrathecal dzp 
indicates that postsynaptic α2-GABAA receptors play a dominant role in antihyperalgesia 
against nerve injury-induced neuropathic pain. This is important because Coull et al. (4, 5) 
have provided data indicating a depolarizing shift in the neuronal chloride gradient potentially 
turning GABAergic inhibition into excitation in the course of CCI neuropathy. The present 
data suggest that dorsal horn GABAA receptors retain an inhibitory action even after 
peripheral nerve injury.  
GABAA receptors on spinal nociceptor terminals have been suggested to inhibit the 
transmission of nociceptive signals through primary afferent depolarization and resulting 
presynaptic inhibition. The sns-α2-/- mice studied here had normal baseline nociceptive 
sensitivity and developed normal inflammatory or neuropathic hyperalgesia. Under conditions 
of very intense nociceptor stimulation or when inflammation-induced changes in the 
expression of chloride transporters further enhance PAD to potentials sufficient of triggering 
action potentials, PAD may on the contrary also exaggerate pain and inflammation through 
so called dorsal root reflexes (28, 40). Under these conditions, input to the dorsal horn from 
one primary afferent nerve fiber could via an interconnected GABAergic interneuron activate 
another primary afferent fiber terminal. In this fiber, the action potential could then propagate 
both anterogradely into the synaptic terminal, and retrogradely along the nerve into the 
peripheral tissue, where it could in case of a peptidergic fibers release proinflammatory 
mediators such as CGRP and substance P. Again, sns-α2-/- mice did not exhibit altered 
hyperalgesia after capsaicin injection and no changes in hyperalgesia or paw swelling after 
capsaicin or zymosan A injection. However, both of these findings do not exclude a 
contribution of PAD to either presynaptic inhibition or dorsal root reflexes, because the 
GABAA receptors remaining in nociceptors of sns-α2-/- mice were apparently sufficient to 
sustain GABAergic membrane currents of normal amplitude.  
It has also been speculated that the antihyperalgesic action spinal benzodiazepines might be 
limited by a possible facilitation of GABAA receptor-mediated dorsal root reflexes. However, 
although GABAergic membrane currents in nociceptive DRG neurons of sns-α2-/- mice were 
less dzp sensitive, we did not observe increased antihyperalgesic effects in any of the pain 
models employed here. 
RESULTS (paper 2) 
- 66 - 
 
ACKNOWLEDGEMENTS 
The authors thank Dr. Rohini Kuner, Heidelberg, for providing sns-cre BAC transgenic mice 
and Isabelle Camenisch for genotyping of all mice. This work has been supported in part by 
a grant from the Swiss National Science foundation (31003A-116064) to H.U.Z.  
 
AUTOR CONTRIBUTIONS 
R.W. performed all behavioral experiments and made the qRT-PCR experiments, U.R. and 
R.K. generated floxed gaba2 mice, P.P. did the electrophysiological experiments, J.P. and 
J.M.F. made all morphological analyses, H.U.Z. designed the experiments, R.W. and H.U.Z. 
wrote the manuscript, all authors made comments to the manuscript.  
 
References 
1. Bohlhalter S, Weinmann O, Mohler H, & Fritschy JM (1996) Laminar 
compartmentalization of GABAA-receptor subtypes in the spinal cord: an 
immunohistochemical study. J Neurosci 16(1):283-297. 
 
2. Ishikawa T, Marsala M, Sakabe T, & Yaksh TL (2000) Characterization of spinal 
amino acid release and touch-evoked allodynia produced by spinal glycine or 
GABA(A) receptor antagonist. Neuroscience 95(3):781-786 (in eng). 
 
3. Roberts LA, Beyer C, & Komisaruk BR (1986) Nociceptive responses to altered 
GABAergic activity at the spinal cord. Life Sci 39(18):1667-1674. 
 
4. Coull JA, et al. (2003) Trans-synaptic shift in anion gradient in spinal lamina I neurons 
as a mechanism of neuropathic pain. Nature 424(6951):938-942. 
 
5. Coull JA, et al. (2005) BDNF from microglia causes the shift in neuronal anion 
gradient underlying neuropathic pain. Nature 438(7070):1017-1021. 
 
6. Moore KA, et al. (2002) Partial peripheral nerve injury promotes a selective loss of 
GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci 
22(15):6724-6731. 
 
7. Ahmadi S, Lippross S, Neuhuber WL, & Zeilhofer HU (2002) PGE(2) selectively 
blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn 
neurons. Nat Neurosci 5(1):34-40. 
 
8. Harvey RJ, et al. (2004) GlyR alpha3: an essential target for spinal PGE2-mediated 
inflammatory pain sensitization. Science 304(5672):884-887. 
 
9. Zeilhofer HU (2008) Loss of glycinergic and GABAergic inhibition in chronic pain--
contributions of inflammation and microglia. Int Immunopharmacol 8(2):182-187. 
 
10. Scholz J, et al. (2005) Blocking caspase activity prevents transsynaptic neuronal 
apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral 
nerve injury. J Neurosci 25(32):7317-7323. 
 
RESULTS (paper 2) 
- 67 - 
11. Knabl J, et al. (2008) Reversal of pathological pain through specific spinal GABAA 
receptor subtypes. Nature 451:330-334. 
 
12. Knabl J, Zeilhofer UB, Crestani F, Rudolph U, & Zeilhofer HU (2009) Genuine 
antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor 
point-mutated mice. Pain 141(3):233-238. 
 
13. Kontinen VK & Dickenson AH (2000) Effects of midazolam in the spinal nerve ligation 
model of neuropathic pain in rats. Pain 85(3):425-431. 
 
14. Barnard EA, et al. (1998) International Union of Pharmacology. XV. Subtypes of 
gamma-aminobutyric acidA receptors: classification on the basis of subunit structure 
and receptor function. Pharmacol Rev 50(2):291-313. 
 
15. Ernst M, Bruckner S, Boresch S, & Sieghart W (2005) Comparative models of 
GABAA receptor extracellular and transmembrane domains: important insights in 
pharmacology and function. Mol Pharmacol 68(5):1291-1300. 
 
16. Wieland HA, Luddens H, & Seeburg PH (1992) A single histidine in GABAA receptors 
is essential for benzodiazepine agonist binding. J Biol Chem 267(3):1426-1429. 
 
17. Rudolph U, et al. (1999) Benzodiazepine actions mediated by specific gamma-
aminobutyric acid(A) receptor subtypes. Nature 401(6755):796-800. 
 
18. Crestani F, et al. (2002) Trace fear conditioning involves hippocampal alpha5 
GABA(A) receptors. Proc Natl Acad Sci U S A 99(13):8980-8985. 
 
19. Low K, et al. (2000) Molecular and neuronal substrate for the selective attenuation of 
anxiety. Science 290(5489):131-134. 
 
20. Sung KW, Kirby M, McDonald MP, Lovinger DM, & Delpire E (2000) Abnormal 
GABAA receptor-mediated currents in dorsal root ganglion neurons isolated from Na-
K-2Cl cotransporter null mice. J Neurosci 20(20):7531-7538. 
 
21. Kanaka C, et al. (2001) The differential expression patterns of messenger RNAs 
encoding K-Cl cotransporters (KCC1,2) and Na-K-2Cl cotransporter (NKCC1) in the 
rat nervous system. Neuroscience 104(4):933-946. 
 
22. Eccles JC, Schmidt R, & Willis WD (1963) Pharmacological Studies on Presynaptic 
Inhibition. J Physiol 168:500-530. 
 
23. Barker JL & Nicoll RA (1972) Gamma-aminobutyric acid: role in primary afferent 
depolarization. Science 176(38):1043-1045. 
 
24. Frank K & Fourtes MGF (1957) Presynaptic and postsynaptic inhibition of 
monosynaptic reflexes. Fed. Proc. 16:39-40. 
 
25. Eccles JC, Eccles RM, & Magni F (1961) Central inhibitory action attributable to 
presynaptic depolarization produced by muscle afferent volleys. J Physiol 159:147-
166. 
 
26. Kullmann DM, et al. (2005) Presynaptic, extrasynaptic and axonal GABAA receptors 
in the CNS: where and why? Prog Biophys Mol Biol 87(1):33-46. 
 
27. Rudomin P & Schmidt RF (1999) Presynaptic inhibition in the vertebrate spinal cord 
revisited. Exp Brain Res 129(1):1-37. 
RESULTS (paper 2) 
- 68 - 
 
28. Willis WD, Jr. (1999) Dorsal root potentials and dorsal root reflexes: a double-edged 
sword. Exp Brain Res 124(4):395-421. 
 
29. Agarwal N, Offermanns S, & Kuner R (2004) Conditional gene deletion in primary 
nociceptive neurons of trigeminal ganglia and dorsal root ganglia. Genesis 38(3):122-
129. 
 
30. Lakso M, et al. (1996) Efficient in vivo manipulation of mouse genomic sequences at 
the zygote stage. Proc Natl Acad Sci U S A 93(12):5860-5865. 
 
31. Akopian AN, et al. (1999) The tetrodotoxin-resistant sodium channel SNS has a 
specialized function in pain pathways. Nat Neurosci 2(6):541-548. 
 
32. Turecek R & Trussell LO (2001) Presynaptic glycine receptors enhance transmitter 
release at a mammalian central synapse. Nature 411(6837):587-590. 
 
33. Bormann J, Hamill OP, & Sakmann B (1987) Mechanism of anion permeation through 
channels gated by glycine and gamma-aminobutyric acid in mouse cultured spinal 
neurones. J Physiol 385:243-286. 
 
34. Ma W, Saunders PA, Somogyi R, Poulter MO, & Barker JL (1993) Ontogeny of 
GABAA receptor subunit mRNAs in rat spinal cord and dorsal root ganglia. J Comp 
Neurol 338(3):337-359. 
 
35. Persohn E, Malherbe P, & Richards JG (1991) In situ hybridization histochemistry 
reveals a diversity of GABAA receptor subunit mRNAs in neurons of the rat spinal 
cord and dorsal root ganglia. Neuroscience 42(2):497-507. 
 
36. Zheng W, et al. (2003) Function of gamma-aminobutyric acid receptor/channel rho 1 
subunits in spinal cord. J Biol Chem 278(48):48321-48329. 
 
37. Kingery WS, Fields RD, & Kocsis JD (1988) Diminished dorsal root GABA sensitivity 
following chronic peripheral nerve injury. Exp Neurol 100(3):478-490. 
 
38. Obata K, et al. (2003) Contribution of injured and uninjured dorsal root ganglion 
neurons to pain behavior and the changes in gene expression following chronic 
constriction injury of the sciatic nerve in rats. Pain 101(1-2):65-77. 
 
39. Baer K, et al. (1999) Postsynaptic clustering of gamma-aminobutyric acid type A 
receptors by the gamma3 subunit in vivo. Proc Natl Acad Sci U S A 96(22):12860-
12865. 
 
40. Cervero F & Laird JM (1996) Mechanisms of touch-evoked pain (allodynia): a new 
model. Pain 68(1):13-23. 
 
41. Schmidt-Supprian M & Rajewsky K (2007) Vagaries of conditional gene targeting. Nat 
Immunol 8(7):665-668. 
 
42. Arbuckle JB & Docherty RJ (1995) Expression of tetrodotoxin-resistant sodium 
channels in capsaicin-sensitive dorsal root ganglion neurons of adult rats. Neurosci 
Lett 185(1):70-73. 
 
43. Pearce RJ & Duchen MR (1994) Differential expression of membrane currents in 
dissociated mouse primary sensory neurons. Neuroscience 63(4):1041-1056. 
 
RESULTS (paper 2) 
- 69 - 
44. Pernia-Andrade AJ, et al. (2009) Spinal endocannabinoids and CB1 receptors 
mediate C-fiber-induced heterosynaptic pain sensitization. Science 325(5941):760-
764. 
 
 
 
RESULTS (paper 3) 
- 70 - 
3.3 Hoxb8-Cre Mice: a Tool for Brain-Sparing Conditional Gene Deletion* 
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Abstract 
The spinal cord is the first site of the temporal and spatial integration of nociceptive signals in 
the pain pathway. Neuroplastic changes occurring at this site contribute critically to various 
chronic pain syndromes. Gene targeting in mice has generated important insights into these 
processes. However, the analysis of global gene-deficient mice is often hampered by 
confounding effects arising from supraspinal sites. Here, we describe a novel Homeobox-8-
Cre (Hoxb8-Cre) mouse line which expresses the Cre recombinase under the transcriptional 
control of the Hoxb8 gene. Within the neural axis of the mice, Hoxb8-Cre expression is found 
in spinal cord neurons and glial cells, and in virtually all neurons of the dorsal root ganglia, 
but spares the brain apart from few cells in the spinal trigeminal nucleus. The Hoxb8-Cre 
mouse line should be a valuable new tool for the in vivo analysis of peripheral and spinal 
aspects of pain.  
 
Introduction 
Noxious (i.e. painful or potentially tissue damaging) stimuli are sensed by specialized nerve 
cells, called peripheral or primary nociceptors, which connect the peripheral tissues with the 
spinal cord dorsal horn, the first site of synaptic processing in the pain pathway. From there, 
nociceptive signals are relayed to higher central nervous system areas where pain finally 
becomes conscious. It is generally accepted that chronic/pathological pain syndromes can 
originate from dysfunctions at all three levels. Persistent activity of peripheral nociceptors as 
well as plastic changes in the spinal and supra-spinal processing of nociceptive stimuli have 
been shown to contribute to these pathologies. In addition, these sites are also critically 
involved in the action of many analgesic drugs, in particular of opioids (Dickenson & Kieffer, 
2006) but also of aspirin-like drugs (cyclooxygenase inhibitors) (Malmberg & Yaksh, 1992a; 
Malmberg & Yaksh, 1992b). Conventional (global) gene targeting has yielded important 
insights into mechanisms of pain and analgesia.  It does however not allow discrimination 
between the different sites, although this was highly desirable in many aspects of basic pain 
research and analgesic drug development. One strategy to address this issue relies on 
conditional gene deletion through the Cre-loxP system. Primary nociceptor-specific gene 
deletion can be achieved with mice expressing the Cre recombinase under the transcriptional 
control of the gene encoding the sensory neuron-specific sodium channel (sns) Nav1.8 
(Agarwal et al., 2004; Akopian et al., 1999). Other mouse lines, Peripherin-Cre (Zhou et al., 
2002) and HtPA-Cre (Pietri et al., 2003), have been reported to express the Cre recombinase 
in primary sensory neurons of dorsal root ganglia. To further discriminate spinal (and 
peripheral) sites from supraspinal sites, we aimed at the generation of a Cre mouse line 
allowing brain-sparing gene deletion. To this end, we generated a novel mouse line 
expressing the Cre recombinase under the transcriptional control of the murine homeobox 
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gene Hoxb8 (Hox-2.4). Hox genes are expressed in spatially and temporally restricted 
domains along the anterior-posterior axis of the body, where they usually show a sharp 
rostral expression boundary . The expression of of the Hoxb8 gene extends to the cervical 
segment C2 (Charité et al., 1995; Deschamps and Wijgerde, 1993). The expression pattern 
described above makes Hoxb8 an appropriate gene to drive Cre expression for brain-sparing 
gene deletion. 
 
Materials and Methods 
Generation of Transgenic Construct and Mice. The Hoxb8-lacZ reporter construct number 
1  (kindly provided by Jacqueline Deschamps (ref.)) was modified by restriction enzymes. 
The 11,410 bp genomic regions 5’ and 3’ between Sal I (Hoxb9, exon1) and ~20 bp 
upstream to the Nru I site (within lacZ) from the Hoxb8-lacZ reporter construct, containing the 
first 1058 bp of the Hoxb8 sequence (whole genomic sequence before ATG starting codon of 
Hoxb8), was fused to a sequence containing a Kozak sequence and ATG starting codon (5’-
ACGCCACCATG-3’) into a cloning vector (pBC SK (+/-), Stratagene). A Cre recombinase 
construct containing a bovine poly (A) sequence was cloned 24 bp  downstream of vector 
sequence (5’-GGACCCAAGAAGAAGAGGAAGGTG-3’) to the ATG starting codon. The final 
linearized construct (12,754 bp) was sequenced, purified for microinjection and injected into 
early state oocytes from C57BL/6 x DBA2 mice. Four transgenic founders were obtained 
which were crossed back to C57BL/6 background for at least 2 generations before crossing 
these Hoxb8-Cre heterozygous mice with the RA/EG  and ROSA26lacZ reporter mouse 
lines. The analyzed mice had a C57BL/6 background of at least 93.75 %.  
 
Southern Blot Analysis. The number of Hoxb8-Cre transgene copies integrated into the 
genome of Hoxb8-Cre mouse line 1403 was determined using quantitative southern blot. A 
probe (749 bp) was generated by PCR using the following primers: FWD: 5’-TTG TTG TGA 
GGC AAG AGA TA-3’ and REV: 5’-TTT ATT GAA TTT TGA GGC G-3’ labelling Hoxb8 
promoter region.  EcoRV digestion of genomic liver DNA resulted in a 4,4 kb wild type and 
transgenic 1,3 kb Hoxb8-Cre band.  
 
LacZ Staining and Immunohistochemistry. To study the pattern of Cre activity the mouse 
lines were crossed with mice from 2 reporter mouse lines, B6.129S4-
Gt(ROSA)26Sortm1Sor/J (ROSA26lacZ) (Soriano, 1999) and B6.129P2-Ager tm1Arnd (RA/EG) 
Constien et al., 2001), as well as with the use of mice carrying a floxed GlyT1 allele (GlyT1fl/fl; 
Slc6a9tm1.1Bois). Co-transgenic progeny (4-6 weeks) from Hoxb8-Cre and ROSA26-lacZ mice 
were histologically analyzed for β-galactosidase activity in cryostat-sections (16 μm) of 
DRGs, spinal cord, brain, liver, heart and kidney (for protocol see Hogan et al., 1994). 
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Counterstaining was performed with acidified (4% acetic acid) hematoxylin. Whole-mount 
embryos (plug was considered as embryonic day E 0.5) were freed of their extraembryonic 
membranes before being fixed in 0.2% glutaraldehyde between 15 and 30 min on ice. LacZ 
staining was performed at 37°C for 1-24 hours (for protocol see  Hogan et al., 1994).  
For immunostaining experiments, mice (age 4-6 weeks, GlyT1 experiments: 10 days) were 
perfused transcardially through the ascending aorta with PBS followed by fixative containing 
4% paraformaldehyde and 0.2% picric acid in 0.15 M phosphate buffer, pH7.4. After 
perfusion, the organs were dissected rapidly and postfixed over night in the same fixative 
solution followed by cryoprotection in PBS containing 30% sucrose over night (until tissue 
blocks sinked). The organs were cut at -40°C into 40 µm sections with a sliding microtome 
HM400 (Micron, Heidelberg). The free-floating sections were washed in Tris-Triton (Tris-
buffer with 0.05% Triton X-100, pH 7.4) and then incubated in a mixture of primary antibodies 
diluted in Tris-Triton containing 2% normal goat serum (NGS) and 0.2% Triton X-100 in a 
moist chamber with continuous agitation (100 rpm) overnight at 4°C. Sections were then 
washed 3 times 10 min in Tris-Triton and incubated for 30 min at room temperature in a 
mixture of secondary antibodies coupled to the fluorochromes Alexa Fluor488 and cyanine 
dye Cy3 (Jackson Immunoresearch, West Grove, PA). Non specific staining was blocked 
with 2% normal goat serum. Sections were washed 3 times 10 min in PBS and mounted on 
gelatine-coated slides, air dried and coverslipped with fluorescence mounting medium (Dako 
Cytomation). Antisera used: Chicken bacterial anti-β-galactosidase 1:3000 (Abcam, ab9361), 
NeuN 1:5000 (Chemicon), rabbit anti-GlyT1a,b 1:1000 (same as being used in the 
publication Zeilhofer et al., 2005). The lacZ stainings and immunostainings were analyzed 
using the Axioskop 2 MOT (Carl Zeiss AG), the Axiocam color (Carl Zeiss AG), Axioplan 2 
(Carl Zeiss AG) and the laser scanning confocal microscope LSM 510 Meta (Carl Zeiss AG). 
Image acquisition parameters were adjusted to the full dynamic range of the photodetector 
and all images from a particular experiment were taken with the same settings. Confocal 
images were processed with the image analysis software Mac Biophotonics ImageJ. 
 
Testing of Paw Withdrawal Reflexes. Behavioral measurements were done on awake, 
free-moving mice (age 9 weeks). The mouse plantar test apparatus (Ugo basile, Italy) was 
used to determine paw withdrawal latencies in response to noxious heat, which was applied 
via an infrared light source. Similarly, dynamic von Frey filaments (IITC) were used to apply 
increasing mechanical pressure to the plantar surface of one hindpaw and mechanical 
stimulus thresholds were recorded in grams. At least 5 measurements were recorded per 
paw and animal. (n = 4-6 mice per group). 
Animal permission for all animal experiments was obtained from the Veterinäramt of the 
Kanton of Zurich (licences 34/2007 and 35/2009). 
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Data and Statistics. Numeric data are presented as mean +/- SEM. In figure 5, the Hoxb8-
Cre and littermate wild type groups were compared with unpaired Student t-test. A value of P 
< 0.05 was considered statistically significant. 
 
Results and Discussion 
Charité et al.  characterized upstream cis-acting regulatory elements of the Hoxb8 gene and 
found that a 11kb DNA segment upstream of the Hoxb8 translational start closely mimicked 
the endogenous Hoxb8 expression pattern. To generate Hoxb8-Cre transgenic mouse lines, 
we fused the 11 kb DNA segment  to a Cre expression cassette and used this construct for 
pronuclear injection (figure 1A). Four transgenic founders were obtained and gave rise to 
four transgenic lines, which were back crossed continuously to the C57BL/6 background and 
maintained in a heterozygous state. Two lines (1403, 1404) showed the desired expression 
pattern on a gross scale (figure 1B).  One of these lines (1403), which carries a single copy 
of the transgene (figure 1C), is described here in detail.  
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Figure 1.  Generation of Hoxb8-Cre mice.  
 
(A) Cloning construct and respective genomic context in the murine locus. Red bars indicate coding 
regions of exons (X). Between Hoxb9- and Hoxb8 genes an artificial sequence (blue letters) 
containing a starting ATG codon was inserted. (B) Hoxb8-Cre-induced lacZ activity in E11.5 embryo. 
(C) Southern blot of EcoRV digested genomic liver DNA from a Hoxb8-Cre transgenic mouse (line 
1403) hybridized with a probe against the Hoxb8 promoter. A hybridization intensity ratio of about 0.6 
between Hoxb8-Cre transgene (1.3 kb) and Hoxb8 wild type (4.4 kb) suggests the presence of a 
single copy of the transgene. 
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To analyze the expression pattern of Hoxb8-Cre-mediated gene recombination along the 
neural axis, Hoxb8-Cre mice were crossed with Rosa26lacZ mice (R26R) . Cryostat sections 
from spinal cords, brains and spinal dorsal root ganglion (DRG) neurons (which harbour the 
somata of peripheral sensory neurons, including nociceptors) were prepared from adult co-
transgenic (Hoxb8-Cretg+/R26R) mice and stained with X-Gal followed by a counterstain with 
acidified hematoxylin. Sagittal and coronal spinal cord sections from adult co-transgenic mice 
revealed a lacZ expression pattern throughout the white and grey matter of the spinal cord in 
a pattern reminiscent of a Nissl staining, suggesting lacZ expression in neurons as well as in 
glial cells (figure 2A). Wild type littermate control sections which were included as controls 
did not show any visible lacZ activity. To determine the rostral Cre expression boundary in 
the Hoxb8-Cre mouse line, coronal and horizontal spinal cord sections representing different 
anterior-posterior spinal cord segments were analyzed. Hoxb8-Cre-induced lacZ expression 
was similar at the lumbar and thoraxic segment, but gradually decreased in a caudo-rostral 
direction within the cervical segment (figure 2C). While full lacZ activity was still observed at 
the cervical segment C7 in both the grey and the white matter, lacZ activity disappeared 
around the cervical segment C4 and became restricted to a few cells scattered in the grey 
matter at cervical segment C2. The brain was largely devoid of lacZ precipitates (figure 2D) 
even after prolonged (24 hours) X-Gal exposure with the exception of a few cells in the spinal 
trigeminal nucleus (figure 2E).  
Hoxb8-Cre-mediated gene recombination was also analyzed in cryostat sections of lumbar 
DRGs from Hoxb8-Cretg+/R26R mice that showed Cre-induced lacZ activity in virtually all cell 
bodies of both small and large DRG neurons, indicating efficient Cre-mediated gene 
recombination in all cell bodies of primary afferent neurons, including primary nociceptors 
(Figure 2B).  
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Figure 2. β-gal activity in co-transgenic Hoxb8-Cretg+/R26R mice in neural tissue.  
 
Counterstaining with acidified hematoxylin. (A) Coronal section of the spinal cord at lumbar segment 
L2. Dorsal horn (dh); ventral horn (vh); white matter (wm). (B) Lumbar dorsal root ganglion. (C) 
Horizontal section of the upper cervical spinal cord and cerebellum (cb) showing a gradual decrease 
of β-gal activity towards more anterior cervical segments. (D) Sagittal brain section showing no visible 
Hoxb8-Cre-induced β-gal activity (E) Sagittal section including brainstem, spinal trigeminal nucleus 
(Sp5C), and cerebellum (cb).  
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We next aimed at determining the types of cells showing Hoxb8-Cre-induced lacZ 
precipitates in the spinal cord. To demonstrate the presence of lacZ in neurons, we 
performed co-immunostainings of coronal spinal cord sections with anti-sera against the 
bacterial β-galactosidase (β−gal) and the neuron-specific nuclear protein (NeuN). β−gal 
immunoreactivity was found in virtually all NeuN-positive neurons (figure 3a,b).  
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Figure 3. Histochemical analysis of co-transgenic progeny of Hoxb8-Cre mice crossed with 
R26R and RA/EG reporter strains.  
 
Neuronal expression analysis (A,B). 
(A) Coronal thoraxic spinal cord section from a co-transgenic Hoxb8-Cretg+/R26R mouse. β−gal (Alexa 
Fluor488; left panel) and NeuN (Cy3; right panel) immunofluorescence on the same section. Scale 
bar: 100 μm.  
(B) Confocal immunofluorescence analysis of a coronal lumbar spinal cord section from a co-
transgenic Hoxb8-Cretg+/R26R mouse. β-gal (Alexa Fluor488), NeuN (Cy3) and merged view in the 
dorsal horn (DH). Scale bar: 20 μm.  
Glial expression analysis (C, D). (C) Coronal section from the lumbar spinal cord of Hoxb8-GlyT1-/- 
and wild type littermate mice showing GlyT1 immunofluorescence (Alexa Fluor488). Scale bar: 100 
μm. (D) Same as (C), but higher magnification and confocal analysis (Alexa Fluor488). Scale bar: 5 
μm.  
Mesodermic expression analysis (E). Coronal spinal cord sections from a Hoxb8-Cretg+/RA/EG 
mouse showing strong EGFP signals in lumbar (L3) spinal sections. No EGFP signals were detectable 
in higher cervical segments (data not shown). Scale bar: 100 μm. 
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Hoxb8-Cre-mediated recombination could also be verified in astrocytes. This was shown 
through the Hoxb8-Cre-mediated (conditional) deletion of glycine transporter type 1 (GlyT1) 
gene, which is abundantly expressed in spinal glial cells (Zafra et al., 1995). Hoxb8-Cre mice 
were crossed with mice carrying floxed GlyT1 alleles (Yee et al, 2006) to generate Hoxb8-
Cretg+/GlytT1flox/flox (Hoxb8-GlyT1-/-) mice. Immunohistochemical analysis of postnatal day 10 
(P10) mice revealed intense GlyT1 immunofluorescence throughout the spinal grey matter of 
wild type  mice, but not in Hoxb8 -GlyT1-/- mice (figure 3 C,D).  
The mesodermic expression pattern in the spinal cord was analyzed with the use of the 
RA/EG reporter strain , which carries a Cre-inducible enhanced green fluorescence protein 
(EGFP) reporter gene in the locus of the receptor for advance glycated end products 
(RA/EG). We analyzed coronal sections at different spinal cord segments of co-trangenic 
progeny from Hoxb8-Cre mice crossed with the RA/EG strain (figure 3 E). At lumbar 
segments, strong Hoxb8-Cre-induced EGFP fluorescence was found in cell layers along 
blood vessels. EGFP fluorescence extended rostrally up to thoraxic segments (approx. T2; 
data not shown). RA/EG reporter mice did not reveal neural Hoxb8-Cre-mediated EGFP 
fluorescence, consistent with previous findings showing that the RA/EG promoter is not 
constitutively active in most neurons (Brett et al., 1993; Constien et al., 2001). 
We next analyzed Hoxb8-Cre-induced lacZ expression in non-neural tissues. Heart and liver 
sections did not reveal any apparent Hoxb8-Cre-induced lacZ staining, whereas kidney 
sections showed strong lacZ activity in about 50% of epithelial cells and in cells suurounding 
blood vessels (figure 4). 
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Figure 4. β-gal activity in co-transgenic Hoxb8-Cretg+/R26R mice in non-neural tissue.  
 
Histological analysis of β−gal activity in 5-6 week old co-transgenic Hoxb8-Cretg+/R26R progeny. 
Counterstain with acidified hematoxylin. Kidney (upper row), heart (middle row), liver (lower row). 
Scale bars represent 100 μm. 
 
 
Finally, the temporal onset of Hoxb8-induced Cre activity was analyzed in co-transgenic 
embryos recovered at embryonic states E9.5 to E15 from Hoxb8-Cre mice crossed with the 
R26R strain. A pronounced lacZ expression pattern very similar to the rostro-caudal 
expression pattern observed in adolescent tissues was found already at embryonic day E9.5 
(data not shown). 
In general, the Hoxb8-Cre-induced lacZ expression pattern described here is very similar to 
that of the endogenous Hoxb8 expression in embryos described earlier (Charité et al., 1995; 
Deschamps & Wjigerde, 1993). Previous in situ hybridization studies localized the 
RESULTS (paper 3) 
- 82 - 
endogenous Hoxb8 expression boundary at cervical segment C2 (Charité et al., 1995). 
When neuroectodermal and mesodermic boundaries were compared in an other in situ 
hybridization study,  the neuroectodermal Hoxb8 expression was found to extend more 
rostrally than the mesodermic expression (6th versus 11/12th somite, respectively) 
(Deschamps & Wijgerde, 1993). Despite these similarities, significant differences exist 
between the Hoxb8-Cre-induced lacZ expression in the mice described here and the 
previously described Hoxb8lacZ mice, where Hoxb8 is replaced by a lacZ cassette 
generated previously .  In these Hoxb8lacZ mice lacZ was more strongly expressed in the 
dorsal than in the vental spinal cord and found only in a subpopulation of DRG neurons. By 
contrast, our transgenic mice expressed Hoxb8-Cre-induced lacZ similarly in the dorsal and 
ventral horn of the spinal cord and in all DRG neurons. This and the small difference in the 
anterior-posterior boundaries of Hoxb8-mediated Cre expression boundaries (posterior shift 
of about 2 segments) are most likely due to integration site effects or the absence of 
regulatory elements of the Hoxb8 gene, located outside the construct . Since insertion of Cre 
transgenes can potentially lead to a loss of function of genes or to copy-number-dependent 
Cre-induced toxicity (Baba et al., 2005; Silver & Livingston, 2001), one prerequisite for the 
use of Hoxb8-Cre mice in pain studies is that they themselves do not show abnormalities in 
the responses to painful stimuli. Exposure to noxious thermal or mechanical stimuli did not 
reveal differences in the nociceptive thresholds of Hoxb8-Cre mice compared to their 
littermate wild type mice (figure 5 A, B). 
In summary, the Hoxb8-Cre transgenic mice described here showed the desired Cre 
expression pattern and should hence be suitable for brain-sparing gene deletion 
experiments. This will be very helpful in the site-specific analysis e.g. of pain-related genes 
which often exhibit a wide-spread expression along the neural axis including peripheral, 
spinal and supraspinal sites. In such studies, our Hoxb8-Cre mice will allow distinguishing 
effects at supraspinal sites from spinal and peripheral effects. 
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Figure 5. Responses to noxious thermal and mechanical stimulation in Hoxb8-Cre mice.  
 
Hoxb8-Cre and wild type littermates (wt) show virtually identical mechanical thresholds (A) and paw 
withdrawal latencies upon exposure to noxious heat (B)  Mean +/- sem. (n = 4-6 mice/group).  
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4. Overall Discussion and Future Perspectives 
 
Possible analgesic effects of systemically administered benzodiazepines have been difficult 
to adress due to their sedative effects. Experiments in GABAA receptor point-mutated (knock-
in) mice, in which specific GABAA receptor subtypes have been rendered insensitive to 
diazepam, allowed to assess this question. Genetic and pharmacological evidence gathered 
in this thesis now clearly indicates that an analgesic effect of benzodiazepines exists after 
spinal application via benzodiazepine-sensitive GABAA receptors containing the α2 and/or 
α3 subunits. Pharmacological tools used subsequently conformed these findings. Systemic 
application of a non-sedative α1-sparing benzodiazepine site ligand (L-838,417) decreased 
hyperalgesia in inflammatory and neuropathic pain (paper 1).   
Importantly, spinally injected diazepam is not effective against pain in non-inflamed or non-
injured animals but only reverses pathologically increased pain sensitivity, a finding that is in 
good agreement with the notion that benzodiazepines are generally not analgesic (Jasmin et 
al., 2004). Therefore its action should be considered as anti-hyperalgesic rather than 
anagesic. The reason for this differential effect is not known. It has been suggested that the 
GABAergic tone (e.g. descending inhibitory pathways) in the nociceptive system is low under 
physiological conditions (Dirig and Yaksh, 1995). According to these findings patients 
suffering from chronic pain associated with a loss of inhibitory neurotransmission in the 
dorsal horn might benefit from the novel non-sedative site-specific GABAA receptor ligands.  
At present, it remains unknown  whether or not these findings can be translated to human 
patients. Clinical evidence suggests that benzodiazepines lack a clear analgesic effect at low 
non-sedative doses. The testing of this hypothesis will require the availability of subtype-
selective benzodiazepine or GABAA receptor ligands. Unfortunatley, L-838,417, the 
compound used in paper 1, possesses undesirable pharmacokinetics in man (Rogawski, 
2006). Oher compounds such TPA023 or SL 651498 (de Haas et al., 2007; de Haas et al., 
2008) possess suitable pharmacokinetics in man, but have either very low intrinsic activity at 
α2-GABAA receptors (Atack et al., 2006) or have a very narrow non-sedative window 
(Griebel et al., 2001). 
Nevertheless, future subtype-selective agonists with suitable pharmacokinetic properties 
might not only be devoid of sedation, but might also prevent other side effects (liability to 
physical dependence, addiction and tolerance development) that currently also restrict or 
even prevent the use of classical benzodiazepines as analgesics. It has already been shown 
that the amnestic effects of classical benzodiazepines involve GABAA receptors containing 
the α1 subunit (Rudolph et al., 2001). Similarly, published evidence suggests that physical 
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dependence does not occur with several α1-sparing agents (TPA023) (Mirza and Nielsen, 
2006) and at least in the case of L-838,417, tolerance against the anti-hyperalgesic effect 
was completely absent during a 9-day treatment period - in striking contrast to morphine, 
which had lost its analgesic activity already within 9 days (paper 1). A recent study provided 
direct evidence that the addictive properties of classicial benzodiazepines depend on α1-
containing GABAA receptors in GABAergic inhibitory neurons in the ventral tegmental area 
(Tan et al.). These findings indicate that subunit-selective benzodiazepines sparing α1 
should be devoid of addiction liability (but see also (Rowlett et al., 2005).  
The situation is significantly less clear with respect to cognition-impairing effects of classicial 
benzodiazepines. Work in mutant mice shows that hippocampus-dependent learning 
probably involves α5-GABAA receptors (Crestani et al., 2002), a finding which is supported 
by the cognition enhancing effects of α5 inverse agonists (Dawson et al., 2006). Experiments 
in paper 1 suggest that α5-GABAA receptors may contribute to spinal antihyperalgesic effects 
under certain conditions (Mirza et al., 2008; Munro et al., 2008). 
The pronounced effect of spinally injected diazepam has also interesting neurobiological 
implications. In the case of the inflammatory pain model, it suggests that the positive 
modulation of GABAA receptors can compensate also for the reduction in glycine-mediated 
neurotransmission that underlies inflammatory hyperalgesia (Ahmadi et al., 2002; Harvey et 
al., 2004). In the neuropathic pain model it was suggested that a depolarizing shift in the 
transmembrane chloride gradient of dorsal horn neurons is a possible mechanisms of 
neuropathic pain (Coull et al., 2003; Coull and Gagnon, 2009). However, the pronounced 
effect of intrathecally applied diazepam suggests that the net effect of GABA in the spinal 
dorsal horn remains inhibitory also in neuropathic pain conditions. 
The second project addressed at the contribution of primary afferent depolarization and 
presynaptic inhibition to spinal benzodiazepine-induced analgesia. It demonstrated that 
under inflammatory conditions a significant part of the α2-GABAA receptor-mediated spinal 
benzodiazepine-induced analgesia originates from GABAA receptors residing on primary 
nociceptors. The remaining α2-GABAA receptor-dependent spinal analgesia could either 
come from activation of postsynaptically located α2-GABAA receptors or, theoretically, from 
α2-GABAA receptors on myelinated Aβ or Aδ fibers, which were not adressed in this study.  
An open question is the possible contribution of supraspinal α2-GABAA receptors to 
analgesia evoked by systemically administered benzodiazepines. The cre transgenic mouse 
described in the third project may help to address this question. Here, the generation and 
characteristics of a new cre mouse line (Hoxb8-cre) have been described which enables 
brain-sparing conditional gene deletion in primary sensory neurons and the spinal cord. This 
mouse line will allow the definition of the contribution of supraspinal α2-GABAA receptors to 
GABAergic pain control. Although analgesia induced by intrathecally injected dzp most 
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probably only involves spinal GABAA receptors, supraspinal α2-GABAA receptors might also 
contribute after systemic administration either directly or through relief from anxiety-induced 
hyperalgesia. On the other hand, supraspinal GABAA receptors most likely of the α1 subtype 
might exert pro-nociceptive actions by increasing the tonic inhibition of antinociceptive fiber 
tracts descending from the periaqueductal gray (PAG) to the rostral ventromedial medulla 
(RVM) and the spinal cord. Conditional Hoxb8-cre-mediated deletion of the GABAA receptor 
α1 subunit will help resolving these questions. 
Targeting fast synaptic neurotransmission in the dorsal horn for the treatment of chronic pain 
might be a novel rational strategy because both inflammatory and neuropathic pain 
pathologies converge at a loss of inhibitory pain control, which probably accounts for the 
most symptoms of chronic pain such as allodynia (pain evoked by even slightest cutaneous 
stimulation). Instead of interfering with signal transduction pathways specific to either 
inflammatory pain or neuropathic pain, restoring synaptic inhibition in the spinal dorsal horn 
should be an effective means against a variety of pain syndromes. In addition to GABAA 
receptors glycine receptors might be another target. Given the distinct expression of GlyRα3 
in the superficial dorsal horn (Harvey et al., 2004), this subunit should be another promising 
target for such pharmacological interventions (see figure below). Yet, so far no compounds 
are available which would act as specific positive allosteric modulators of inhibitory glycine 
receptors (Laube et al., 2002). 
In summary, the results from this dissertation contribute to the development of a rational 
basis for the development of subtype-selective GABAA receptor ligands for the treatment of 
chronic pain, which is often refractory to classical analgesics.  
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Inhibitory synapses in the spinal dorsal horn circuitry allowing fast synaptic inhibitory 
transmission.  
 
At least three populations of neurons contribute to the synaptic inhibition in the spinal dorsal horn.  
(1) GABAergic and glycinergic neurons, which are mainly located in the deeper dorsal horn, are 
activated by mechano-sensitive Aδ or Aβ fibers. Many of these neurons release both GABA and 
glycine simultaneously. The dominant glycine receptor isoform at these synapses contains the α3 
subunit, while GABAA receptors at this site probably mainly contain α2 and/or α3 subunits in addition 
to a β and a γ2 subunit.  
(2) GABAergic and glycinergic inhibition also comes from inhibitory fiber tracts descending from the 
rostral ventromedial medulla.  
(3) Inhibitory interneurons located in the superficial dorsal horn probably form mainly axo-axonic 
synapses with the spinal terminals primary afferent nerve fibers, which express the α2 and α3 
subunits. Adapted and rearranged from (Zeilhofer et al., 2009). 
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6. Appendices 
6.1 Abbreviations  
ACSF artificial cerebrospinal fluid 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ANOVA analysis of variance 
BBB blood brain barrier 
BDNF brain-derived neurotrophic factor 
β-gal β-galactosidase 
BOLD blood oxygen level dependency 
cAMP cyclic adenosine monophosphate 
CB1 cannabinoid receptor type1 
CCI chronic constriction injury 
CFA complete Freund's adjuvant 
CGRP calcitonin gene-related peptide 
CNS central nervous system 
COX cyclooxygenase 
cre/loxP cyclization recombination protein/locus of X-over P1 (bacteriophage1) 
CTB cholera toxin B subunit 
Cy3 indocarbocyanin 
DMSO dimethyl sulphoxide 
DRG dorsal root ganglion 
DRR dorsal root reflexes 
Dzp/DZP diazepam 
EGFP enhanced green fluorescent protein 
EP2 prostaglandin E2 receptor 
EPSC excitatory postsynaptic current 
EPSP excitatory postsynaptic potential  
GABA γ-aminobutyric acid  
GABAA γ-aminobutyric acid GABA    receptor GABA type A receptor 
GABAB γ-aminobutyric acid GABA    receptor GABA type B receptor 
GAD65/67 glutamate decarboxylase isoform 65/ isoform 67 
gDNA genomic deoxyribonucleic acid 
GlyRα3 Glycine receptor α3 subtype 
GlyT1/GlyT2 glycine transporter type 1 / type 2 
GPCR G protein coupled receptor 
Hox homeobox 
IASP International Association for the Study of Pain 
IB4 isolectin IB4 
i.p. intraperitoneal 
i.t. intrathecal 
KCC2 K+-Cl- cotransporter type 2 
LTP long-term potentiation 
mPGES-1 microsomal prostaglandin E2 synthase-1 
mRNA messenger ribonucleic acid 
NeuN neuronal nuclei (neuron-specific nuclear protein) 
NGF nerve growth factor 
NK1  neurokinin 1 
NKCC1 Na+-K+-2Cl- cotransporter type 1 
NMDA N-methyl-D-aspartic acid 
NSAID non-steroidal anti-inflammatory drug 
PAD primary afferent depolarization 
PAG periaqueductal gray 
PAN primary afferent nociceptor 
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PGE2 prostaglandin E2 
PKA protein kinase A 
PKC(γ) protein kinase C (gamma) 
PNL partial nerve ligation 
qRT-PCR quantitative real-time polymerase chain reaction 
RA/EG receptor for advance glycated end products 
RVM rostral ventromedial medulla 
SMT spinomesencephalic tract 
SNI spared nerve injury 
SNL spinal nerve ligation 
SP substance P 
SRT spinoreticular tract 
trkB tyrosine kinase receptor B 
TRPV1 (VR1) transient receptor potential vanilloid type 1 
TTX tetrodotoxin 
SD standard deviation 
SEM standard error of the mean 
SNS sensory neuron-specific sodium channel 
VGCC voltage-gated calcium channel 
Veh vehicle 
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Illustration of René Descartes’ theory of pain, in which a painful sensation travels along a specific 
“pain pathway” up the spinal cord to be perceived in the brain,1664. 
 
 
 
 
